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ABSTRACT: We designed 39 new 2-phenylindole derivatives
as potential anticancer agents bearing the 3,4,5-trimethox-
yphenyl moiety with a sulfur, ketone, or methylene bridging
group at position 3 of the indole and with halogen or methoxy
substituent(s) at positions 4−7. Compounds 33 and 44 strongly
inhibited the growth of the P-glycoprotein-overexpressing
multi-drug-resistant cell lines NCI/ADR-RES and Messa/Dx5.
At 10 nM, 33 and 44 stimulated the cytotoxic activity of NK
cells. At 20−50 nM, 33 and 44 arrested >80% of HeLa cells in
the G2/M phase of the cell cycle, with stable arrest of mitotic
progression. Cell cycle arrest was followed by cell death. Indoles
33, 44, and 81 showed strong inhibition of the SAG-induced Hedgehog signaling activation in NIH3T3 Shh-Light II cells with IC50
values of 19, 72, and 38 nM, respectively. Compounds of this class potently inhibited tubulin polymerization and cancer cell growth,
including stimulation of natural killer cell cytotoxic activity and repression of Hedgehog-dependent cancer.
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■ INTRODUCTION
Microtubules (MTs) are cylindrical structures mainly composed
of α,β-tubulin heterodimers. MT assembly is a highly dynamic
process because of continuous transitions between polymer-
ization and depolymerization. MTs are involved in a number of
essential cellular functions, such as maintenance of cell shape, cell
motility, intracellular transport, and cell division. Interfering with
the MT dynamic equilibrium, by either inhibiting tubulin
polymerization or blocking MT disassembly, prevents proper
MT function and ultimately leads to cell death. Interfering with
these cellular processes has resulted in a productive strategy for
the development of efficient anticancer agents.1−4
Colchicine (1),5,6 combretastatin A-4 (CSA4, 2)7 (Chart 1),
and theCatharanthus alkaloids vincristine (VCR) and vinblastine
(VBL) inhibit MT assembly by preventing tubulin polymer-
ization, and this leads to cell death. In contrast, taxoids and
epothilones bind at a luminal site on the β-subunit8,9 following
entry into the MT through pores in its wall10 that are shaped by
various tubulin subunits on the MT surface. Some evidence
indicates a transient binding of MT-stabilizing agents at a specific
pore site. Paclitaxel (PTX) stimulates MT polymerization and
stabilization at high concentrations, whereas lower concen-
trations of PTX inhibit MT dynamics with little effect on the
proportion of tubulin in the polymer.11
The development of MT-targeting drugs with different mecha-
nisms of action12 has achieved substantial progress. However, drug
resistance, toxicity, and unwanted side effects still remain unsolved
problems. Therefore, the quest for new MT inhibitors as com-
ponents of improved anticancer treatments remains mandatory.13
Arylthioindole (ATI) derivatives are potent inhibitors of
tubulin polymerization that bind to the colchicine site on
β-tubulin. A number of ATIs proved to be more potent than 1, 2,
VBL, and PTX and thus are potential new anticancer agents.14,15
ATI derivatives bearing an aromatic ring at position 2 of the
indole (A region) inhibit tubulin polymerization and cancer cell
growth. These compounds hamper mitotic progression, thus
causing cells to undergo apoptosis (i.e., ATI 3: tubulin assembly,
IC50 = 3.3 μM;MCF-7, IC50 = 52 nM)
14,15 (Chart 1). In contrast,
chemical modification of positions 4−7 of the indole (D region)
were not exhaustively explored, although a few ATI derivatives
bearing an ethoxycarbonyl functionality at position 2 and a
halogen atom or a methoxy group at position 5 proved to be
potent tubulin assembly inhibitors (i.e., ATI 4: tubulin assembly,
IC50 = 2.0 μM;MCF-7, IC50 = 13 nM).
16 It should also be noted
that major differences in structure−activity relationships (SARs)
were found in comparing ATIs with the 3-aroylindoles reported
by Hsieh and co-workers.17 These compounds are characterized
by the presence of a methoxy group at position 6 of the indole.
Docking studies of compounds 1 and 3 into the colchicine site
of tubulin showed a good superimposition of the trimethox-
yphenyl (TMP) moieties and of the tropolone ring C with the
phenyl core of the indole14,15 (Figure 1). These findings
suggested that appropriate substituents at positions 4−7 of the
indole could resemble the methoxy and carbonyl groups at
positions 10 and 9, respectively, of the tropolone ring. Docking
simulations with PLANTS,18 using our methodology described
previously,19 revealed binding poses consistent with the previous
ATI series: (i) the TMP group formed polar interactions with
βCys241, βMet259, and βLeu255; (ii) the indole NH established
a H-bond with αThr179; (iii) the phenyl ring at position 2 of the
indole set up hydrophobic interactions with the βLys254 and
βLeu248 side chains. In comparison with 3, the chlorine atom(s)
of 10, 18, 28, 37, and 44 fitted into a new hydrophobic pocket
formed by the βLys353, βAsn258, βMet259, and αVal181
residue side chains (Figure 1S, Supporting Information). The
7-fluoro atom of 40, the most potent tubulin polymerization
inhibitor within the series, behaved as a H-bond acceptor with
αVal181 (Figure 2S, Supporting Information). The methoxy
group of 33 mimicked the corresponding group at position 10
of 1, resembling its interaction with the εN of βLys353.
These observations prompted us to undertake SAR inves-
tigations at positions 4−7 of the indole (Chart 1 and Table 1).
Figure 1. Proposed binding modes of 1 (cyan), 3 (gray), and 44
(orange). Tubulin is represented as a cartoon for the α-subunit (red)
and β-subunit (green). Residues forming interactions with the ATI D
region are depicted in white.
Chart 1. General Structures of Compounds 1−45
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We planned the synthesis of 2-phenyl-1H-indole derivatives,
keeping the 2-phenyl group fixed at position 2, because of the
better metabolic profile compared to that of indole derivatives
bearing an ester function at this position.15
■ CHEMISTRY
2-Phenyl-3-((3,4,5-trimethoxyphenyl)thio)-1H-indoles 6, 8, 11,
13, 15, 18, 21, 23, 25, 28, 31, 33, 35, 37, 40, 42, and 44 were
prepared by reacting 2-phenylindoles 46−62 with bis(3,4,5-
trimethoxyphenyl) disulfide16 in the presence of sodium hydride
at 130 °C (120 W) for 2 min according to our previously
reported venting-while-heating microwave-assisted procedure20
(Scheme 1). Microwave-assisted Friedel−Crafts reaction of the
indoles 46−62 with 3,4,5-trimethoxybenzoyl chloride in the
presence of AlCl3 in 1,2-dichloroethane at 110 °C (150 W) for
2 min furnished the corresponding methanones 7, 9, 12, 14, 16,
19, 22, 24, 27, 29, 32, 34, 36, 38, 41, 43, and 45.21 Methylene
derivatives 10, 17, 20, 25, 30, and 39 were prepared by reducing
the appropriate ketones with a borane−tetrahydrofuran complex
in acetonitrile/methanol at 50 °C for 1 h22 (10, 20, 25, 30, and
39) or with triethylsilane/trifluoroacetic acid in 1,2-dichloro-
ethane at 250 °C (250 W) for 20 min23 (17).
Reaction of the appropriate 1-methyl-2-nitrobenzene with
benzaldehyde in the presence of sodium ethoxide in anhydrous
dimethyl sulfoxide at 25 °C for 12 h furnished the alcohols
63−65. After oxidation of 63−65 to ketones 66−68 with
pyridium chlorochromate in anhydrous dichloromethane at
25 °C for 1.5 h, the nitro group was reduced to amino with tin(II)
chloride dihydrate/1 N HCl in acetic acid at reflux temperature
for 12 h; the intermediate aminoketone underwent intra-
molecular cyclization to give the corresponding 2-phenylindoles
46, 54, and 56 (Scheme 2a).24 2-Phenylindoles 47−49, 55, 57,
and 61 were prepared by reaction of the N-(2-tolyl)benzamides
69−74 with tert-butyllithium in anhydrous tetrahydrofuran
at −40 °C.25 Amides 69−74 were obtained by treatment of an
appropriate o-toluidine with benzoyl chloride in the presence of
triethylamine in anhydrous tetrahydrofuran at reflux temperature
for 2 h (Scheme 2b). Polyphosphoric acid-mediated cyclization
at 110 °C for 1 h of phenylhydrazones 75−80, prepared from the
appropriate phenylhydrazine hydrochloride and acetophenone
in the presence of sodium acetate in ethanol at 80 °C (250W) for
5 min,26 gave the corresponding 2-phenylindoles 50−52, 58, 60,
and 6227 (Scheme 2c).
■ RESULTS AND DISCUSSION
Inhibition of Tubulin Polymerization, the Binding of
Colchicine to Tubulin, and MCF-7 Breast Cancer Cell
Growth. We synthesized compounds 6−45, including ATI
Scheme 1. Synthesis of Compounds 6−45a
aReagents and reaction conditions: (a) bis(3,4,5-trimethoxyphenyl)
disulfide, anhydrous DMF, closed vessel, 130 °C, 120 W, 2 min, venting-
while-heating, 20−77%; (b) 3,4,5-trimethoxybenzoyl chloride, anhydrous
AlCl3, 1,2-dichloroethane, closed vessel, 110 °C, 150 W, 2 min, 20−78%;
(c) (10, 20, 25, 30, and 39) borane−tetrahydrofuran complex,
acetonitrile/methanol, 50 °C, 1 h, 10−41%; (d) (17) triethylsilane,
trifluoroacetic acid, 1,2-dichloroethane, 250 °C, 250 W, 20 min, 15%.
Scheme 2. Synthesis of Intermediates 46−62a
aReagents and reaction conditions: (a) benzaldehyde, sodium
ethoxide, anhydrous DMSO, 25 °C, 12 h, 40−44%; (b) pyridinium
chlorochromate, anhydrous dichloromethane, 25 °C, 1.5 h, 16−40%;
(c) tin(II) chloride dihydrate/1 N HCl, acetic acid, reflux temperature,
12 h, 19−24%; (d) benzoyl chloride, triethylamine, anhydrous THF,
reflux temperature, 2 h, 49−88%; (e) (i) tert-butyllithium, anhydrous
THF, −40 °C, Ar stream; (ii) 1 h, 0 °C; (iii) 25 °C, 12 h, 18−52%;
(f) acetophenone, sodium acetate, ethanol, open vessel, 80 °C, 250 W,
5 min, cooling-while-heating, 25−95%; (g) polyphosphoric acid,
110 °C, 1 h, 25−82%.
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derivatives and some corresponding ketone and methylene
compounds, to obtain SAR information on the substituent(s)
introduced at positions 4−7 of the indole nucleus. The activities
of compounds 6−45 as inhibitors of tubulin polymerization in
vitro, the growth of MCF-7 human breast cancer cells, and
the binding of [3H]colchicine to tubulin are shown in Table 1.
Table 1. Inhibition of Tubulin Polymerization, Binding of Colchicine to Tubulin, andGrowth ofMCF-7Human Breast Carcinoma
Cells by Compounds 6−45 and References 1−5
compd R X tubulin assembly IC50 ± SD
a (μM) MCF-7 IC50 ± SD
b,c (nM) colchicine binding inhibitionc,d (% ± SD)
6 4-Br S 2.4 ± 0.1 400 ± 70 33 ± 2
7 4-Br CO >20 (partial activity)e 430 ± 100 ndf
8 4-Cl S 1.6 ± 0.07 290 ± 50 48 ± 5
9 4-Cl CO 3.6 ± 0.2 260 ± 50 38 ± 3
10 4-Cl CH2 17 ± 0.2 >5000 nd
11 4-F S 1.7 ± 0.07 80 ± 30 80 ± 0.4
12 4-F CO 1.6 ± 0.08 65 ± 7 63 ± 1
13 4-MeO S >20 (partial activity)e 1400 ± 300 nd
14 4-MeO CO >20 (no activity)g >5000 nd
15 5-Br S 1.3 ± 0.1 320 ± 100 39 ± 3
16 5-Br CO >40 530 ± 100 nd
17 5-Br CH2 4.0 ± 0.5 700 ± 300 31 ± 2
18 5-Cl S 1.5 ± 0.2 280 ± 70 49 ± 5
19 5-Cl CO >20 330 ± 100 nd
20 5-Cl CH2 4.4 ± 0.8 310 ± 10 38 ± 3
21 5-F S 1.5 ± 0.1 300 ± 0 61 ± 4
22 5-F CO 13 ± 0.4 240 ± 90 nd
23 5-OMe S 2.1 ± 0.01 200 ± 80 58 ± 0.5
24 5-OMe CO 8.3 ± 1 170 ± 60 nd
25 5-OMe CH2 3.5 ± 0.4 100 ± 0 41 ± 0.9
26 6-Br S 1.9 ± 0.2 9.0 ± 2 87 ± 0.6
27 6-Br CO 1.3 ± 0.2 30 ± 2 86 ± 0.4
28 6-Cl S 1.2 ± 0.2 20 ± 10 88 ± 3
29 6-Cl CO 1.4 ± 0.06 35 ± 7 71 ± 5
30 6-Cl CH2 1.6 ± 0.01 55 ± 20 72 ± 6
31 6-F S 2.4 ± 0.2 80 ± 20 74 ± 2
32 6-F CO 10 ± 0.4 600 ± 0 nd
33 6-MeO S 1.1 ± 0.1 1.3 ± 0.6 96 ± 1
34 6-MeO CO 1.2 ± 0.06 30 ± 10 95 ± 0.4
35 7-Br S 1.6 ± 0.2 25 ± 5 82 ± 1
36 7-Br CO 1.7 ± 0.1 4.0 ± 0.5 72 ± 0.3
37 7-Cl S 1.3 ± 0.2 50 ± 10 82 ± 0.3
38 7-Cl CO 1.8 ± 0.05 9.0 ± 1 69 ± 0.5
39 7-Cl CH2 2.4 ± 0.2 200 ± 0 50 ± 4
40 7-F S 1.0 ± 0.1 20 ± 9 92 ± 0.3
41 7-F CO 1.7 ± 0.1 30 ± 0 67 ± 3
42 7-OMe S 1.2 ± 0.01 19 ± 10 87 ± 2
43 7-OMe CO 1.8 ± 0.1 200 ± 0 62 ± 3
44 6,7-Cl2 S 1.2 ± 0.1 7.0 ± 3 92 ± 2
45 6,7-Cl2 CO 1.5 ± 0.03 15 ± 5 93 ± 0.7
1 3.2 ± 0.4 5.0 ± 1 nd
2 1.0 ± 0.1 13 ± 3 98 ± 0.6
3h 3.3 ± 0.1 52 ± 7 nd
4i 2.0 ± 0.2 13 ± 3 93 ± 0.8
5i 2.5 ± 0.3 42 ± 10 76 ± 0.2
aInhibition of tubulin polymerization. Tubulin was at 10 μM in the assembly assay. bInhibition of growth of MCF-7 human breast carcinoma cells.
cCompounds that inhibited tubulin assembly with IC50 ≤ 5 μM were tested in the cellular and colchicine binding assays.
dInhibition of
[3H]colchicine binding. Tubulin was at 1 μM. Both [3H]colchicine and inhibitor were at 5 μM. ePartial inhibition at 20 μM. fNo data. gLittle or no
activity at 20 μM. hReference 15. iReference 16.
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.5b00310
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The majority of these new derivatives (23 compounds: 8, 11, 12,
15, 18, 21, 26−30, 33−38, and 40−45) inhibited tubulin
polymerization with IC50 values in the 1.0−2.0 μM range, as
compared with colchicine (1) (IC50 = 3.2 μM) and CSA4 (2)
(IC50 = 1.0 μM).
Among the group of compounds 6−14, bearing the
substituent at position 4 of the indole, the 4-chloro derivative
8 inhibited tubulin assembly with an IC50 of 1.6 μM and was
2.2-fold more active than the corresponding ketone 9 (IC50 =
3.6 μM). The thio/keto 4-fluoro derivatives 11 (IC50 = 1.7 μM)
and 12 (IC50 = 1.6 μM) were almost equipotent as tubulin
assembly inhibitors and showed the greatest inhibition of MCF-7
cell growth (11, IC50 = 80 nM; 12, IC50 = 65 nM). Neither the
bromine atom nor the methoxy group was found among the
most active compounds with position 4 substituents in both the
thio and ketone series. In terms of effects on MCF-7 cell growth,
there is no evident major difference between the thio and keto
series with substituents at position 4, although the data are
limited. Compounds 15−25 were characterized by substituents
at position 5 of the indole nucleus. As tubulin polymerization
inhibitors, the arylthioindoles 15 (IC50 = 1.3 μM), 18 (IC50 =
1.5 μM), 21 (IC50 = 1.5 μM), and 23 (IC50 = 2.1 μM) were all
significantly more potent than the corresponding ketones 16, 19,
22, and 24 and slightly more active than the methylene
compounds 17, 20, and 25. The tubulin inhibitory activity of
these compounds seemed to be weakly affected by the nature of
the substituent. In contrast to the corresponding ester
derivatives, all these compounds were weak inhibitors of MCF-
7 cell growth with IC50 ≥ 100 nM (compare 4 (IC50 = 13 nM)
with 23, and 5 (IC50 = 42 nM) with 18). Furthermore, within the
limitations of the data, there are no major differences in the
effects on MCF-7 cell growth dependent on the bridging group
(thio, ketone, or methylene).
Compounds 26−34, bearing the substituent at position 6,
inhibited tubulin polymerization with IC50 < 2.5 μM, with the
exception of the 6-fluoro derivative 32 (IC50 = 10 μM). As
inhibitors of MCF-7 cell growth, ketones were less potent than
the corresponding thio derivatives. Among the thio derivatives,
the 6-bromo (26, IC50 = 9.0 nM) and 6-methoxy (33, IC50 =
1.3 nM) derivatives were the most potent cell growth inhibitors.
Compounds 35−43, with the substituent at position 7 of the
indole, were all potent inhibitors of tubulin assembly, with IC50 <
2.5 μM. With the exception of 39 and 43, these compounds
potently inhibited the growth of the MCF-7 cells, with
compounds 36 (IC50 = 4 nM) and 38 (IC50 = 9 nM) being the
most active. In contrast to the findings with the 6-substituted
indoles, in the 7-substituted series, the bromo and chloro ketones
tended to be more potent than the corresponding thio
counterparts as inhibitors of MCF-7 cell growth (compare 26
and 27 with 35 and 36, and 28 and 29 with 37 and 38). Finally,
we tried to join the features of 28 and 29 with those of 37
and 38 to further enhance activity. This effort yielded the
6,7-dichloroindole derivatives 44 and 45, both of which
indeed were highly potent inhibitors of tubulin polymerization
(IC50 = 1.2 and 1.5 μM, respectively) and MCF-7 cell growth
(IC50 = 7 and 15 nM, respectively). A SAR summary of tubulin
polymerization inhibition (TPI) and inhibition of MCF-7 cell
growth of ATI derivatives 6−45 is depicted in Figure 2.
The results obtained from the docking simulations described
above provided us with a general binding mode that was able to
justify the biological activity of the compounds. However, there
were some exceptions that could not be fully rationalized (7, 13,
14, and 16), and we did not see any correlation between docking
scores and experimental data. This has prompted us to further
investigate the binding mode of ATIs with another set of docking
simulations using a more recent tubulin structure (PDB code
4O2A),29 crystallized at higher resolution than the structure used
previously (2.50 Å vs 3.58 Å, respectively).29 Furthermore, we
have performed the docking calculations with two other software
programs that each rely on a different search algorithm: Glide30
and Autodock.31
The docking results obtained from these simulations were
entirely consistent with the one obtained using PLANTS.
Indeed, we observed a virtually identical binding pose for the
ATIs, regardless of the tubulin structure or the algorithm used in
the simulation (Figure 3S, Supporting Information). It should be
noted that we have not observed any correlation between the
docking score and the experimental data in any of the
calculations (Table 1S, Supporting Information). This observa-
tion is not entirely surprising considering this correlation is rarely
observed.28
We analyzed the data from Table 1 comparing the microtuble
assembly inhibitory concentrations (μM) with the percent
inhibition of colchicine binding since these data provide an
indirect measure of the affinity of the compounds for the
colchicine site (Figure 3). The inhibition of tubulin polymer-
ization was in good agreement with inhibition of colchicine
binding. The compounds that inhibited tubulin assembly with
IC50 values in the 1.0−1.5 μM range inhibited colchicine binding
by 39−96% (mean value of 79%), those that inhibited assembly
with IC50 values in the 1.6−2.0 μM range inhibited colchicine
binding by 48−82% (mean value of 70%), and assembly inhibi-
tors with IC50 values in the 2.1−3.0 μM range inhibited colchi-
cine binding by 33−74% (mean value of 53%) (CSA4: assembly,
Figure 2. SAR summary of tubulin polymerization inhibition (TPI) and
inhibition of MCF-7 cell growth of ATI derivatives 6−45.
Figure 3. Correlation between inhibition of tubulin assembly (IC50
values, μM) and inhibition of colchicine binding (%). Data of ATI
derivatives 6−45 are shown as open circles. The black circle represents
CSA4 as the reference compound.
Journal of Medicinal Chemistry Article
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IC50 = 1.0 μM; colchicine binding inhibition, 98%). We analyzed
the MCF-7 cell growth inhibition (nM) of ATIs 6−45 with the
corresponding inhibitory concentration (μM) on tubulin
assembly (Figure 4SA, Supporting Information) and with
the percent inhibition on the binding of [3H]colchicine to
tubulin (Figure 4SB). In these plots we observed good
correlation of the antiproliferative data with the biochemical
data, particularly with the ligand binding data (inhibition of
colchicine binding).
Cell Growth Inhibition. ATIs 33 and 44 were assayed as
growth inhibitors of a panel of cancer cell lines, including MDA-
MB-468, MDA-MB-436, MDA-MB-231, A-549, MV4−11, NB4,
and NCI-H1975, using PTX as the reference drug. As a growth
inhibitor of MDA-MB-468, MDA-MB-436, and MDA-MB-231
breast cancer cells, using the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay, ATI 33 at 72 h
showed IC50 values of 37, 62, and 39 nM, respectively, with the
corresponding values for 44 being 33, 75, and 47 nM,
respectively (Table 2). Compounds 33 and 44 induced a dose-
and time-dependent growth inhibition of each treated cell line
(Figures 5S−10S, Supporting Information). Compounds 33 and
44 inhibited the human acute myelocytic leukemia (AML) cell
lines MV4−11 and NB4, showing at 48 h IC50 values of 2.5 and
10.5 nM, and 4 and 10 nM, respectively. As growth inhibitors of
the A-549 and NCI-H1975 human lung adenocarcinoma cancer
cells bearing the KRAS mutation and resistance to EGFR
inhibitors, respectively, ATIs 33 and 44 yielded at 72 h IC50
values in the nanomolar concentration range.
Multi-Drug-Resistant (MDR) Cell Lines. Compounds 33
and 44 were evaluated as inhibitors of the ovarian carcinoma cell
line OVCAR-8 and its cognate P-glycoprotein (Pgp)-over-
expressing line NCI/ADR-RES and of the human uterine
sarcoma cell line Messa and its cognate MDR line Messa/Dx5,
using 1, 2, vinorelbine (VRB), VBL, and PTX as reference
compounds (Table 3). The reference agents 1, VRB, VBL, and
PTX weakly inhibited these MDR cell lines. Compounds 33 and
44 and the reference 2 were potent inhibitors of the MDR cell
lines. ATI 33 (IC50 = 2.5 ± 1 nM) was comparable to 2 (IC50 =
1.8 ± 1 nM) as an inhibitor of the NCI/ADR-RES cell line, and
44 (IC50 = 4.5± 1 nM) was comparable to 2 (IC50 = 2.6± 1 nM)
in the Messa/Dx5 cells.
Arrest of Mitotic Progression and Concomitant Cell
Death Induction. To assess whether the growth-suppressive
effect of 33 and 44 reflected their antimitotic activity, we assessed
their ability to induce mitotic arrest. We previously found that
treatment with 20 nM VBL effectively arrested the cell cycle of
HeLa cells in mitosis; at lower concentrations VBL did not fully
prevent mitotic progression, such that cells assemble defective
mitotic spindles, “slip” through the mitotic checkpoint, and
progress toward aberrant chromosome segregation.14 We
examined HeLa cell cultures treated with 20, 50, and 100 nM
33 or 44 in DMSO, 20 nM VBL, or DMSO vehicle. Treatments
were carried out for 24 h, allowing all cells to enter mitosis during
the treatment. Cell cultures were then harvested, and their cell
cycle profile was analyzed by flow cytometry after incubation
with propidium iodide (PI) to reveal their genomic DNA content
(linear scale). ATIs 33 and 44 at 20 nM induced >80% of HeLa
cells to arrest with a G2/M genomic content, similar to VBL; very
few cells progressed past the G2/M phase (Figure 4A). Thus,
both 33 and 44 effectively arrested mitotic progression and
prevented mitotic slippage, and hence the generation of hyper-
diploid or polyploid cells. To assess whether G2/M-arrested cells
underwent cell death over time, PI-stained cell samples were
analyzed by plotting their DNA content on a logarithmic scale to
resolve the sub-G1 region, in which hypodiploid cells represent
the terminal products of cell death. ATIs 33 and 44 at 20 nM
induced both cell death and concomitant G2/M phase arrest and
were comparable to VBL; these effects were even more
substantial at 50 nM (Figure 4B). The induction of cell death
by 33 seemed to be superior to 44 at all tested concentrations.
Biparametric analysis after simultaneous incubation of non-
permeabilized cells with annexin V, which reacts with
phosphatidylserine residues on the outer cell membrane during
early apoptosis, and PI, to which viable cells are not
spontaneously permeable, discriminates early and late stages of
apoptotic cell death (Figure 4C) from necrotic cells, which are
permeable to PI but do not react with annexin V. We found that
33 and 44 induced cell death with apoptotic-like phenotypic
features with comparable effectiveness and early-to-late kinetics
as observed with VBL.
ATIs 33 and 44 Strongly Inhibit Mitotic MT Assembly.
To correlate cell cycle arrest and cell death induction with
inhibition of MT dynamics in HeLa cells, we employed
immunofluorescence (IF) to examine the effects of ATIs on
tubulin andMTs. HeLa cells were treated with 20 or 50 nM 33 or
44 for 24 h, the same conditions that induced cell cycle arrest
(Figure 4), and then processed for tubulin IF and examined
under fluorescence microscopy. We found that at both
concentrations 33 or 44 arrested cells in mitosis with a
Table 2. Growth Inhibition of theMDA-MB-468,MDA-MB-436, MDA-MB-231, A-549, MV4-11, NB4, andNCI-H1975 Cell Lines
by Compounds 33 and 44 and Reference PTX
IC50 ± SD (nM)
compd MDA-MB-468a MDA-MB-436a MDA-MB-23a MV4−11b (AML_M9) NB4b (AML_M3) A-549a NCI-H1975a
33 37 ± 0.5 62 ± 1 39 ± 1.2 2.5 ± 2.1 4 ± 1 28 ± 6 195 ± 158
44 33 ± 0.3 75 ± 1.1 47 ± 0.1 10.5 ± 0.7 10 ± 4 120 ± 10 305 ± 122
PTX 5 ± 1 8 ± 1.5 7 ± 2 ndc 2.3 ± 0.3 7 ± 2 2.5 ± 5
aIncubation time was 72 h. bIncubation time was 48 h. cNo data.
Table 3. Inhibition of Growth of the OVCAR-8 and
NCI/ADR-RES, and Messa and Messa/Dx Cell Line Pairs by
Compounds 33 and 44 and Reference Compounds 1, 2, VRB,
VBL, and PTXa
IC50 ± SD (nM)
compd OVCAR-8 NCI/ADR-RES Messab Messa/Dx5b
33 4.3 ± 1 2.5 ± 1 20.7 ± 1.7 28.0 ± 1.0
44 14 ± 2 10 ± 4 3.5 ± 0.9 4.5 ± 1.9
1 30 ± 1 420 ± 100 11 ± 6 329 ± 166
2 2.8 ± 1 1.8 ± 1 2.7 ± 2 2.6 ± 1
VRB 300 ± 0 5000 ± 1000 ndc nd
VBL 15 ± 7 200 ± 0 3 ± 2 144 ± 61
PTX 3.7 ± 1 6000 ± 500 4 ± 1 1764 ± 477
aInhibition of growth of the indicated cell lines. bIncubation time was
72 h. cNo data.
Journal of Medicinal Chemistry Article
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prometaphase-like appearance. Consistent with the absence of
hyperdiploid cells in flow cytometry analysis, both ATIs at 20 nM
or higher effectively prevented mitotic slippage. At 20 nM, the
ATIs inhibited MT polymerization and left tubulin foci and/or
small asters of short MT fragments (an example is shown in
Figure 5, right, middle panel). The proportion of mitotic cells
displaying this inhibited MT phenotype was very similar to that
observed with VBL (Figure 5, left). Raising the ATI
concentrations to 50 nM yielded a phenotype with no
recognizable mitotic MT remnants, but only tubulin aggregates
that formed an unstructured meshwork throughout the mitotic
cells (Figure 5, right, top panel). In summary, the newly
synthesized ATIs strongly affect cellular MT polymerization,
resulting in effective inhibition of formation of the mitotic
apparatus, particularly when used at 50 nM, and this phenotype
was associated with a durable mitotic arrest and concomitant
induction of cell death.
Inhibition of PC-3, RD, and HepG2 Cancer Cell Growth.
We determined the effects of ATIs 33 and 44 as growth
inhibitors of the human prostate cancer PC-3, rhabdomyosarco-
ma RD, and human liver hepatocellular carcinoma HepG2 cell
lines, with VBL and PTX as reference compounds (Table 4).
ATIs 33 and 44 strongly inhibited these cell lines at nanomolar
concentrations and were superior to the references VBL and
PTX. Compound 33 was generally more effective than 44 as an
inhibitor of the growth of these three cell lines.
PC-3, RD, and HEPG2 cell cultures were treated for 24 h with
increasing concentrations of ATIs 33 and 44 and of PTX as the
reference drug at 500, 1000, and 2000 nM. After treatment, cells
and vehicle controls (0.1% DMSO) were incubated with PI to
analyze their DNA content in flow cytometry assays. Both ATIs
arrested cell cycle progression in all three cell lines at low
concentrations. ATIs 33 and 44 induced an accumulation in the
G2/M phase in PC-3 and RD cells, as did PTX, whereas in
HepG2 cells these compounds caused a stronger effect on
cell cycle progression as compared with the reference drug
(Figure 11S, Supporting Information).
After a 24 h exposure and subsequent incubation in drug-free
medium for 24 h, the PC-3, RD, and HepG2 cell lines treated
with 33 or 44 showed a strong accumulation of cells in G2/M
(Figure 6).Moreover, 33 and 44 induced an irreversible cell cycle
arrest at concentrations of 500, 1000, and 2000 nM in the PC-3
and RD cells.
A correlation between cell cycle arrest and cell death was
investigated by exposing the cells to a 500, 1000, or 2000 nM
concentration of 33, 44, or PTX, followed by incubation with
Figure 4. (A) Cell cycle profiles of HeLa cell cultures exposed to 33, 44,
or VBL for 24 h at the indicated concentrations. The percentage of cells
with 2C (G1 phase, black bars), 4C (G2/M phases, white bars), or
between 2C and 4C (S phase, dashed bars) genomic DNA content is
shown. Mean values were calculated from three independent experi-
ments. (B) Flow cytometry analysis of PI-stained cells with sub-G1
DNA content, representing terminal cell death, after 24 h. Mean values
were calculated from four independent experiments. (C) Distribution of
cells simultaneously processed for annexin V reactivity and PI
incorporation, representing early (reactive to annexin V, not permeable
to PI) and late (reactive to both annexin V and PI) stages of the cell
death process in cultures treated for 24 h. Mean values were calculated
from three independent experiments.
Figure 5.Mitotic phenotypes in HeLa cell cultures exposed to ATIs 33
and 44 for 24 h and processed for tubulin IF (in red). The bar graph on
the left indicates the statistical distribution of the cytological phenotypes
depicted under the indicated conditions. The frequency of scored
phenotypes is shown as the percentage of all counted mitotic figures
(330−400 counted mitotic figures per condition). Gray bars represent
the frequency of mitotic cells with severe inhibition of tubulin
polymerization, with no recognizable MTs and unstructured tubulin
aggregates (exemplified in the top IF panel). Purple bars represent the
frequency of mitotic cells with inhibited MT polymerization, yielding
short MT stretches (middle panel). Black bars represent the frequency
of normal mitoses with polymerizedMT arrays forming a bipolar spindle
(bottom panel).
Table 4. Growth Inhibition of PC-3, RD, and HepG2 Cell
Lines by Compounds 33 and 41 and References VBL and PTX
IC50
a ± SD (nM)
compd PC3 RD HepG2
33 0.3 ± 0.06 0.2 ± 0.04 0.1 ± 0.02
44 19 ± 1 16 ± 1.3 62 ± 2
VBL 766 ± 1000 53 ± 2.5 81 ± 2.4
PTX 4900 ± 1.3 >10000 2600 ± 1.5
aIncubation time was 48 h.
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.5b00310
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fluorescently conjugated annexin V and PI (Figure 7). All the cell
lines treated with 33 or 44 at 500 nM showed higher rates of cell
death than the same populations treated with 500 nM PTX. A
dose−response trend in cell death was observed in the RD cell
line after a 48 h exposure with either 44 or 33 (Figure 7B) and in
the PC3 and HepG2 cell lines following treatment with PTX
(Figure 7A,C).
Inhibition of T98G and U343MG Cancer Cell Growth.
Malignant gliomas develop from gradual accumulation of
multiple genetic alterations, resulting in either activation of
oncogenes or inactivation of tumor suppressor genes.32 Human
glioblastoma multiforme T98G and U343MG cells show typical
hallmarks of glioblastoma multiforme tumors in patients. We
evaluated the ability of compounds 33 and 44 to inhibit the
growth of T98G and U343MG cancer cells, which show different
genetic profiles for the expression of key cell survival proteins,
such as p53, MDM2, EGFR, RB, cyclin D, and MMPs.33
Treatment of T98G and U343MG cells with increasing
concentrations of 33 or 44 for 24, 48, or 72 h significantly
inhibited cell growth in a dose- and time-dependent manner
(Figures 12S and 13S, Supporting Information). The IC50 values
were calculated taking into account the relative doubling time
(CDT),34,35 after 48 h for the T98G cells and after 72 h for the
U343MG cells. As a cell growth inhibitor, compound 33 yielded
IC50 values of 15.2 ± 1.6 nM in T98G cells and 0.5 ± 0.05 nM in
U343 cells; for 44, IC50 values of 16.3± 1.5 nMnM in T98G cells
and 0.6 ± 0.05 nM nM in U343 cells were obtained.
Expression of MICA and MICB Ligands in HeLa Cells,
Resulting in Enhanced Natural Killer (NK) Cell Degranu-
lation. In previous studies,36 treatment of HeLa and HepG2
tumor cell lines with sodium butyrate, a potent repressor of
histone deacetylases that causes spindle abnormalities and
mitotic arrest, resulted in up-regulation of the expression of
NK cell receptor-activating ligands MICA and MICB at both the
mRNA and protein levels and in enhanced susceptibility of both
cell lines to NK lysis. We evaluated the expression of NKG2D
and DNAM-1 ligands in HeLa cells after treatment with ATI 33,
37, or 44, in particular whether the compounds could modulate
their expression. We first characterized HeLa cell growth
inhibition by 33, 37, or 44, at a sublethal concentration after a
48 h treatment (MTT assay). HeLa cells were more sensitive to
33 and 44 (IC50 = 10 nM) than to 37 (IC50 = 76 nM). After a 48 h
treatment with 10 nMATI, flow cytometric biparametric analysis
of HeLa cells by annexin V/PI staining showed only a weak
increase of early apoptotic cells compared to control cultures
(Figure 14S, Supporting Information).
NK cell receptor-activating ligand analysis by combined IF and
flow cytometry revealed a different modulation of NKG2D and
DNAM-1 ligands in ATI-treated HeLa cells after a 48 h
treatment with sublethal doses. ATIs 33, 37, and 44 behaved as
strong enhancers of MICA, ULBP3, and PVR expression, while
treatment with the compounds had weaker effects on MICB,
ULBP1, and ULBP2 ligand expression (Figure 8) and no effect on
the expression of the Nec-2 ligand (data not shown). Interest-
ingly, (1-(3-aminophenyl)-1H-pyrrol-3-yl)(3,4,5-trimethoxyphenyl)-
methanone, a potent tubulin polymerization inhibitor belonging to
the ARAP class,37 was unable to induce theNKG2D andDNAM-
1 ligands (data not shown). The expression of the ligand surface
on treated HeLa cells was not accompanied by a corresponding
increase in mRNA levels, as indicated by real-time PCR data
(Figure 15S, Supporting Information).
On the basis of these findings, we evaluated whether ATIs 33
and 44 would increase NK cell degranulation toward HeLa cells.
The expression of the lysosomal marker CD107a, which
correlates with NK cell cytotoxicity,38 was evaluated by IF and
flow cytometry analysis by gating on NK cells upon their
interaction with treated or untreated HeLa cells, used as targets.
The up-regulation of NKG2D and DNAM-1 ligands was verified
before the degranulation assay (data not shown). The expression
of CD107a on NK cells contacting treated HeLa target cells
indicated that those cells were more susceptible to NK cell lysis
(Figure 9).
Hedgehog-Inhibiting Activity. The hedgehog (Hh)
signaling pathway is deeply involved in tumorigenesis, and
inhibitors of the Hh pathway have shown great potential as
cancer therapeutics. In recent years, an ever-growing interest in
the Hh pathway has led to the development of a variety of small
molecules targeting key Hh components, i.e., smoothened
(Smo), sonic hedgehog protein (Shh), and Gli1.39 Currently,
some antagonists of Smo, the positive signaling transducer in the
Hh pathway, are undergoing clinical trials.
We wished to investigate whether ATI compounds, like the
structurally related ARAP derivatives,37 could behave as
inhibitors of Hh signaling. We selected three highly potent
ATI derivatives, 33, 44, and 2-(1H-imidazol-1-yl)-3-((3,4,5-
trimethoxyphenyl)thio)-1H-indole (81),15 and their effects were
evaluated by a luciferase assay performed in NIH3T3 Shh-Light
II (Shh-LII) cells. In these cells, in which is stably incorporated an
Figure 6. Cell cycle analysis of PC-3 (A), RD (B), and HepG2 (C) cells
treated with 0.1% DMSO or 500, 1000, or 2000 nM 33, 44, or PTX for
24 h, followed by a 24 h recovery in drug-free medium. Histograms
represent the percentage of cells with G0/G1, S, and G2/M DNA
content expressed as mean values ± SD of three independent
experiments.
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.5b00310
J. Med. Chem. 2015, 58, 5789−5807
5796
D
ow
nl
oa
de
d 
by
 U
N
IV
ER
SI
TA
 D
I R
O
M
A
 L
A
 S
A
PI
EN
ZA
 o
n 
Se
pt
em
be
r 1
4,
 2
01
5 
| ht
tp:
//p
ubs
.ac
s.o
rg 
 
Pu
bl
ic
at
io
n 
D
at
e 
(W
eb
): 
Ju
ly 
20
, 2
01
5 | 
doi
: 1
0.1
021
/ac
s.jm
edc
hem
.5b
003
10
Hh-responsive (Gli-RE) reporter, the induction of the pathway
occurs following treatment with the Smo agonist SAG. ATIs 33,
44, and 81 showed a strong reduction of luciferase activity in cells
treated with SAG in a dose-dependent manner (Figure 10),
yielding IC50 values of 19, 72, and 38 nM, respectively. The
treatment did not decrease the control Renilla luciferase activity,
preventing any cytotoxicity-mediated effects on the inhibition of
Hh signaling. To address the ability of these compounds to affect
D283 medulloblastoma cell proliferation and survival, we
performed a trypan blue count assay. The in vitro treatment
with ATIs 33, 44, and 81 at 1 μM impaired cell growth and the
percentage of cell death, as shown in Figure 16S, Supporting
Information.
Hh inhibitors are attracting ever-growing attention because of
benefits displayed in the treatment of Hh-dependent cancers,
such as medulloblastomas.40 However, the problem of drug
resistance to Smo mutations, arising during clinical treatment,
has led to a quest for new Hh inhibitors. ATIs 33, 44, and 81
showed potent inhibition of the Hh signaling pathway,
suggesting that the ATI class has potential as Hh-dependent
anticancer agents.
Metabolic Stability. Compounds 33 and 44 were examined
in a microsomal stability assay in comparison with 7-ethoxy-
coumarin and propranolol as control compounds, using both
human and mouse liver microsomes, to estimate compound
stability to phase I oxidative metabolism (Table 5). Compound
Figure 7.Cell death cytometric analysis of PC-3 (A), RD (B), and HepG2 (C) cells treated with 0.1% DMSO or 500, 1000, or 2000 nM 33, 44, or PTX
for 48 h. Flow cytometric profiles of cell populations following treatment with DMSO or 2000 nM 33 or 44 are at the top of each panel (annexin
V−FITC staining on the x axis and PI on the y axis). Histograms represent the percentage of cells in early apoptosis (annexin V−FITC staining) and late
apoptosis (annexin V−FITC and PI staining) expressed as mean values ± SD calculated from three independent experiments.
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.5b00310
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44 showed metabolic stability of 25.6 and <3 μL/min/mg of
protein in mouse and human liver microsomes, respectively.
Compound 33 showed medium metabolic stability with human
liver microsomes and low to medium metabolic stability with
mouse liver microsomes (relative stabilities are defined in
footnote a of Table 5).
Aqueous Solubility. The solubility in aqueous pH 7.4 buffer
of compounds 33 and 44 was measured in a high-throughput
screening solubility assay. The solubility of compound 33 was
about 1 μM, while, under the same conditions, compound 44
showed a solubility of 3.2 μM (Table 5).
Figure 8. ATIs 33, 37, and 44 up-regulate DNAM-1 and NKG2D ligands in HeLa cells. NKG2D and DNAM-1 ligand surface expression was analyzed
by flow cytometry after a 48 h treatment with the indicated ATI compound. Data are representative of one out of three independent experiments.
Figure 9.NK cell-mediated killing of HeLa cells increased after a 48 h treatment with ATI 33 or 44. Results are expressed as the percentage of CD107a+
cells after subtraction of the percentage of the control antibody and represent one of two independent experiments. The basal CD107a expression on
NK cells was about 2%.
Figure 10. Inhibition of endogenous Hh signaling in Shh-LII cells by 33,
44, and 81. Dose−response curve of the indicated compounds in SAG-
treated cells in comparison with untreated Shh-Light II cells as a control
(CTR). The treatment time was 48 h, and normalization was against
Renilla luciferase. Data are from three independent experiments. Error
bars indicate SD. An asterisk indicates P = 0.05 vs CTR.
Table 5. Metabolic Stability with Human and Mouse
Liver Microsomesa and Aqueous Solubility of
Compounds 33 and 44
clearanceb,c
(μL/min/mg of protein)
compd
human liver
microsomes
mouse liver
microsomes
solubilityd at
pH 7.4 (μM)
33 15.2 ± 8.0 43.1 ± 7.9 0.99 ± 0.13
44 <3 25.6 ± 1.7 3.18 ± 0.50
7-ethoxycoumarin 209 ± 10.2 710.8 ± 1.2
propranolol 19.1 ± 2.2 235.1 ± 24.1
aMetabolic stability: <3, good; 3−60, medium; >60, low. bResults
are expressed as the mean ± SD, n = 2. cThe standard compounds
7-ethoxycoumarin and propranolol showed metabolic stability in
agreement with the literature and internal validation data REF. dHigh-
throughput screening solubility assay.
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.5b00310
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■ CONCLUSION
We designed 39 new 2-phenylindole derivatives as potential
anticancer agents bearing the 3,4,5-trimethoxyphenyl moiety
linked through a sulfur, ketone, or methylene bridging group at
position 3 of the indole and with halogen or methoxy
substituent(s) at positions 4−7. Twenty-three new derivatives
inhibited tubulin polymerization with IC50 values of 1.0−2.0 μM
and inhibited colchicine binding with a mean value of >70%;
15 derivatives inhibited the growth of human MCF-7 cells with
IC50 ≤ 50 nM.
Compounds 33 and 44, representative members of this series,
uniformly inhibited at nanomolar concentration a panel of cancer
cells, including MDA-MB-468, MDA-MB-436, MDA MB-231,
MV4−11, NB4, A-549, NCI-H1975, T98G, and U343 cells. As
inhibitors of PC-3, RD, andHepG2 cancer cell growth, 33 and 44
were superior to the references VBL and PTX. ATI 33 and 44
were comparable to 2 as inhibitors of the MDR NCI/ADR-RES
and Messa/Dx5 cell lines. Besides the ability to inhibit tubulin
polymerization, for which they were originally designed, ATIs 33
and 44 exhibited an unexpected stimulation of the cytotoxic
activity of NK cells. Our findings demonstrated that 33 and 44 at
doses of 10 nM, which did not severely affect cell viability,
increased NKG2D and DNAM-1 ligand up-regulation of HeLa
cells, resulting in an enhanced stimulation of NK cell cytotoxic
activity. This novel effect of ATIs, elicited at sublethal doses,
along with a stronger expression of NK cell receptor-activating
ligand, led to an increased propensity of NK cells to degranulate
against tumor cells. At higher concentrations of 20−50 nM, ATIs
33 and 44 induced >80% of HeLa cells to arrest with a G2/M
DNA content, an effect similar to that observed with VBL, with
very few cells progressing past the 4N G2/M phase. These
compounds stably arrested mitotic progression, prevented
mitotic slippage and the ensuing formation of aneuploid
cellsa hallmark of aggressive cancersand induced cell
death. These findings suggest that the new ATIs 33 and 44 can
arrest proliferation of cancer cells with effectiveness comparable
or superior to that obtained with VBL. ATIs 44 and 81 showed
strong inhibition of the Hh signaling pathway, inhibiting
medulloblastoma D283 cells with IC50 values of 72 and 38 nM,
respectively.
In summary, these novel ATI compounds show potential to
treat cancer via both MT-based and MT-independent pathways.
Even at low concentrations where the ATIs do not fully prevent
the assembly of the mitotic apparatus, and hence mitotic cell
death, these agents effectively up-regulate NK ligands and trigger
an alternative cytotoxic response via NK cells. Here we have
described the broad potential of the new ATIs in an in-depth
characterization of the cell response to increasing drug
concentrations. We aim to assess whether specificMT-associated
proteins (MAPs) can modulate cell sensitivity to these drugs and
favor one pathway over the other. Such MAPs may serve as
effective biomarkers to predict the prevalent response to ATI
treatment. Compounds 33 and 44 represent novel lead
compounds that will prompt further development of the ATI
class to obtain new promising anticancer agents with enhanced
stimulation of NK cell cytotoxic activity and repression of
Hh-dependent cancers. Derivative 44 showed higher metabolic
stability than 33 in human and mouse liver microsomes and
greater water solubility. The present results highlight the
therapeutic potential of the ATI class as anticancer agents and
prompt further developmental studies.
■ EXPERIMENTAL SECTION
General Chemistry Procedures. Microwave-assisted reactions
were performed on a CEM Discover SP single-mode reactor. The
instrument settings were controlled with PC-running CEM Synergy
1.49 software. Closed vessel experiments were carried out in capped
microwave-dedicated vials (10 mL) with a cylindrical stirring bar (length
8 mm, diameter 3 mm). Open vessel experiments were carried out in
100 mL round-bottom flasks equipped with a Dimroth reflux condenser
and a cylindrical stirring bar (length 20 mm, diameter 6 mm). Stirring,
temperature, irradiation power, maximum pressure (Pmax), PowerMAX
(simultaneous cooling-while-heating), ActiVent (simultaneous venting-
while-heating), and ramp and hold times were set as indicated. The
temperature of the reaction was monitored by an external fiber optic
temperature sensor. After completion of the reaction, the mixture
was cooled to 25 °C via air-jet cooling. Melting points (mp’s) were
determined on a Stuart Scientific SMP1 apparatus and are uncorrected.
Infrared (IR) spectra were run on a PerkinElmer SpectrumOne FT-ATR
spectrophotometer. Band position and absorption ranges are given in
inverse centimeters. Proton nuclear magnetic resonance (1H NMR)
spectra were acquired on a Bruker 400 MHz FT spectrometer in the
indicated solvent by TopSpin 2.1 software and the files processed
by MestreLab Research S.L. MestreReNova 6.2.1−769 software.
Chemical shifts are expressed in δ units (ppm) from tetramethylsilane.
Multiplicities are indicated as s (singlet), d (doublet), t (triplet), q
(quartet), m (multiplet), br (broadened), br s (broadened singlet), and
coupling constants (J) are reported in hertz. Flash chromatography
was carried out on an Interchim Spot II Flash system, using Merck
SuperVarioFlash D26 cartridges packed with Merck Geduran 60
(0.040−0.063 mm) silica gel. Column chromatography was performed
on columns packed with alumina from Merck (70−230 mesh) or silica
gel from Macherey-Nagel (70−230 mesh). Aluminum oxide thin-layer
chromatography (TLC) cards from Fluka (aluminum oxide-precoated
aluminum cards with fluorescent indicator visualizable at 254 nm) and
silica gel TLC cards from Macherey-Nagel (silica gel-precoated
aluminum cards with fluorescent indicator visualizable at 254 nm)
were used for TLC. Developed plates were visualized by a Spectroline
ENF 260C/FE UV apparatus. Organic solutions were dried over
anhydrous sodium sulfate. Evaporation of solvents was carried out on a
Büchi Rotavapor R-210 equipped with a Büchi V-850 vacuum controller
and a Büchi V-700 or V-710 vacuum pump. All commercially available
reagents were used without further purification. Elemental analyses of
the compounds were found within ±0.4% of the theoretical values. The
purity of the tested compounds was determined by high-pressure liquid
chromatography (HPLC) and was >95%. The HPLC system (Dionex
UltiMate 3000, Thermo Fisher Scientific Inc.) was equipped with an SR-
3000 solvent rack, an LPG-3400SD quaternary analytical pump, a TCC-
3000SD column compartment, a DAD-3000 diode array detectorn and
an analytical manual injection valve with a 20 μL loop. Compounds were
dissolved in acetonitrile (10 mg/mL). HPLC analysis was performed
by using an Acclaim 120 C18 reversed-phase column (5 μm, 4.6 ×
250 mm, Thermo Fisher Scientific Inc.) at a temperature of 30 ±
1 °C, an isocratic gradient (acetonitrile:water = 90:10), a flow rate of
1.0 mL/min, and detector signals 254 and 365 nm. Chromatographic
data were acquired and processed by Chromeleon 6.80 software
(Thermo Fisher Scientific Inc.).
Synthesis of Compounds 6−45. General Procedure for the
Preparation of 6, 8, 11, 13, 15, 18, 21, 23, 26, 28, 31, 33, 35, 37, 40,
42 , and 44 . E xample : 4 -B romo-2-pheny l -3 - ( ( 3 ,4 ,5 -
trimethoxyphenyl)thio)-1H-indole (6). A mixture of 4-bromo-2-
phenyl-1H-indole (46) (0.27 g, 1 mmol), bis(3,4,5-trimethoxyphenyl)
disulfide (0.44 g, 1.1 mmol), and sodium hydride (0.053 g, 2.2 mmol;
60% in mineral oil) in anhydrous DMF (3 mL) was placed into the
microwave cavity (closed vessel mode, Pmax = 250 psi). Starting
microwave irradiation of 120Wwas used, the temperature being ramped
from 25 to 130 °C, with rapid stirring and venting (pressure set point
100 psi, times at set point 100, delta pressure 20 psi). Once 130 °C was
reached, taking about 1 min, the reaction mixture was held at this
temperature for 2min. Themixture was diluted with water and extracted
with ethyl acetate. The organic layer was washed with brine and dried.
Removal of the solvent gave a residue that was purified by flash
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.5b00310
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chromatography (silica gel, ethyl acetate/n-hexane as eluent) to furnish
6 (0.13 g, 27%). Mp: 202−205 °C (from ethanol). 1H NMR (CDCl3):
δ 3.66 (s, 6H), 3.79 (s, 3H), 6.37 (s, 2H), 7.10 (t, J = 7.8 Hz, 1H), 7.38−
7.41 (m, 5H), 7.71 (d, J = 6.7 Hz, 2H), 8.72 (br s, disappeared on
treatment with D2O, 1H) ppm. IR: ν 3344 cm
−1. Anal. (C23H20BrNO3S
(470.38)) C, H, Br, N, S.
4-Chloro-2-phenyl-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole
(8). Synthesized as 6, starting from 4-chloro-2-phenyl-1H-indole (47).
Yield: 62%. Mp: 178−180 °C (from ethanol). 1H NMR (DMSO-d6):
δ 3.54 (s, 6H), 3.57 (s, 3H), 6.26 s, 2H), 7.10−7.11 (m, 1H), 7.18−7.20
(m, 1H), 7.44−7.54 (m, 4H), 7.77−7.80 (m, 2H), 12.51 (br s,
disappeared on treatment with D2O, 1H) ppm. IR: ν 3345 cm
−1. Anal.
(C23H20ClNO3S (425.93)) C, H, Cl, N, S.
4-Fluoro-2-phenyl-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole
(11). Synthesized as 6, starting from 4-fluoro-2-phenyl-1H-indole (48).
Yield: 30%. Mp: 168−170 °C (from ethanol). 1H NMR (DMSO-d6):
δ 3.53 (s, 6H), 3.56 (s, 3H), 6.28 (s, 2H), 6.80−6.85 (m, 1H), 7.14−7.19
(m, 1H), 7.32 (d, J = 8.0 Hz, 1H), 7.44 (t, J = 7.1 Hz, 1H), 7.51 (t, J =
7.1 Hz, 2H), 7.80−7.82 (m, 2H), 12.30 (br s, disappeared on treatment
with D2O, 1H) ppm. IR: ν 3307 cm
−1. Anal. (C23H20FNO3S (409.47))
C, H, F, N, S.
4-Methoxy-2-phenyl-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole
(13). Synthesized as 6, starting from 4-methoxy-2-phenyl-1H-indole
(49). Yield: 41%. Mp: 133−136 °C (from toluene). 1H NMR (CDCl3):
δ 3.66 (s, 6H), 3.78 (s, 6H), 6.44 (s, 2H), 6.57−6.59 (m, 1H), 7.05 (d,
J = 8.2 Hz, 1H), 7.18 (t, J = 7.7 Hz, 1H), 7.38−7.48 (m, 3H), 7.73 (d, J =
7.2 Hz, 2H), 8.52 (br s, disappeared on treatment with D2O, 1H) ppm.
IR: ν 3261 cm−1. Anal. (C24H23NO4S (421.51)) C, H, N, S.
5-Bromo-2-phenyl-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole
(15). Synthesized as 6, starting from 5-bromo-2-phenyl-1H-indole (50).
Yield: 18%. Mp: 152−155 °C (from ethanol). 1H NMR (DMSO-d6):
δ 3.53 (s, 6H), 3.56 (s, 3H), 6.27 (s, 2H), 7.32−7.35 (m, 1H), 7.44−7.58
(m, 5H), 7.86−7.88 (m, 2H), 12.29 (br s, disappeared on treatment with
D2O, 1H) ppm. IR: ν 3316 cm
−1. Anal. (C23H20BrNO3S (470.38)) C, H,
Br, N, S.
5-Chloro-2-phenyl-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole
(18). Synthesized as 6, starting from 5-chloro-2-phenyl-1H-indole (51).
Yield: 20%.Mp: 158−160 °C (from ethanol). 1HNMR (CDCl3): δ 3.65
(s, 6H), 3.78 (s, 3H), 6.33 (s, 2H), 7.21−7.24 (m, 1H), 7.36−7.49 (m,
4H), 7.66−7.67 (m, 1H), 7.77−7.80 (m, 2H), 8.69 (br s, disappeared on
treatment with D2O, 1H) ppm. IR: ν 3319 cm
−1. Anal. (C23H20ClNO3S
(425.93)) C, H, Cl, N, S.
5-Fluoro-2-phenyl-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole
(21). Synthesized as 6, starting from 5-fluoro-2-phenyl-1H-indole (52).
Yield: 26%. Mp: 158−160 °C (from toluene). 1H NMR (DMSO-d6):
δ 3.54 (s, 6H), 3.57 (s, 3H), 6.30 (s, 2H), 7.1 (t, J = 8.0 Hz, 1H), 7.16 (d,
J = 9.2 Hz, 1H), 5.45 (t, J = 7.2 Hz, 1H), 7.50−7.55 (m, 3H), 7.88 (d,
J = 7.4 Hz, 2H), 12.21 (br s, disappeared on treatment with D2O, 1H)
ppm. IR: ν 3231 cm−1. Anal. (C23H20FNO3S (409.47)) C, H, F, N, S.
5-Methoxy-2-phenyl-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole
(23). Synthesized as 6, starting from 5-methoxy-2-phenyl-1H-indole
(53). Yield: 20% as an oil. 1H NMR (CDCl3): δ 3.63 (s, 6H), 3.77 (s,
3H), 3.83 (s, 3H), 6.35 (s, 2H), 6.90−6.93 (m, 1H), 7.10−7.11 (m, 1H),
7.32−7.46 (m, 4H), 7.76−7.77 (m, 2H), 8.58 (br s, disappeared on
treatment with D2O, 1H) ppm. IR: ν 3337 cm
−1. Anal. (C24H23NO4S
(421.51)) C, H, N, S.
6-Bromo-2-phenyl-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole
(26). Synthesized as 6, starting from 6-bromo-2-phenyl-1H-indole (54).
Yield: 22%. Mp: 200−203 °C (from ethanol). 1H NMR (DMSO-d6):
δ 3.57 (s, 3H), 3.58 (s, 6H), 6.78 (s, 2H), 7.23−7.27 (m, 3H), 7.35−7.41
(m, 3H), 7.48 (d, J = 8.3 Hz, 1H), 8.09 (s, 1H), 12.40 (br s, disappeared
on treatment with D2O, 1H) ppm. IR: ν 3320 cm
−1. Anal.
(C23H20BrNO3S (470.38)) C, H, Br, N, S.
6-Chloro-2-phenyl-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole
(28). Synthesized as 6, starting from 6-chloro-2-phenyl-1H-indole (55).
Yield: 25%. Mp: 207−210 °C (from ethanol). 1H NMR (DMSO-d6):
δ 3.54 (s, 6H), 3.57 (s, 3H), 6.29 (s, 2H), 7.14 (dd, J = 1.1 and 7.7 Hz,
1H), 7.43−7.55 (m, 5H), 7.87 (d, J = 7.9 Hz, 2H), 12.23 (br s,
disappeared on treatment with D2O, 1H) ppm. IR: ν 3319 cm
−1. Anal.
(C23H20ClNO3S (425.93)) C, H, Cl, N, S.
6-Fluoro-2-phenyl-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole
(31). Synthesized as 6, starting from 6-fluoro-2-phenyl-1H-indole (56).
Yield: 37% as an oil. 1H NMR (CDCl3): δ 3.64 (s, 6H), 3.78 (s, 3H),
6.35 (s, 2H), 6.96 (t, J = 8.8 Hz, 1H), 7.14 (d, J = 9.0 Hz, 1H), 7.41−7.50
(m, 3H), 7.58−7.59 (m, 1H), 7.78 (d, J = 8.0 Hz, 2H), 8.56 (br s,
disappeared on treatment with D2O, 1H) ppm. IR: ν 3320 cm
−1. Anal.
(C23H20FNO3S (409.47)) C, H, F, N, S.
6-Methoxy-2-phenyl-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole
(33). Synthesized as 6, starting from 6-methoxy-2-phenyl-1H-indole
(57). Yield: 24%. Mp: 121−124 °C (from toluene). 1H NMR (DMSO-
d6): δ 3.54 (s, 6H), 3.60 (s, 3H), 3.81 (s, 3H), 6.31 (s, 2H), 6.77 (dd,
J = 2.2 and 8.6 Hz, 1H), 6.97 (d, J = 2.0 Hz, 1H), 7.34−7.42 (m, 2H),
7.50 (t, J = 7.4 Hz, 2H), 7.85 (d, J = 7.2 Hz, 2H), 11.88 (br s, disappeared
on treatment with D2O, 1H) ppm. IR: ν 3322 cm
−1. Anal. (C24H23NO4S
(421.51)) C, H, N, S.
7-Bromo-2-phenyl-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole
(35). Synthesized as 6, starting from 7-bromo-2-phenyl-1H-indole (58).
Yield: 39%. Mp: 142−145 °C (from toluene). 1H NMR (DMSO-d6):
δ 3.54 (s, 6H), 3.57 (s, 3H), 6.29 (s, 2H), 7.08 (t, J = 7.7 Hz, 1H), 6.97
(d, J = 7.7 Hz, 1H), 7.43−7.54 (m, 5H), 7.82 (d, J = 7.1 Hz, 1H), 12.11
(br s, disappeared on treatment with D2O, 1H) ppm. IR: ν 3335 cm
−1.
Anal. (C23H20BrNO3S (470.38)) C, H, Br, N, S.
7-Chloro-2-phenyl-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole
(37). Synthesized as 6, starting from 7-chloro-2-phenyl-1H-indole (59).
Yield: 77%. Mp: 62−65 °C (from ethanol). 1H NMR (CDCl3): δ 3.66
(s, 6H), 3.78 (s, 3H), 6.36 (s, 2H), 7.12−7.17 (m, 1H), 7.43−7.57
(m, 4H), 7.58−7.60 (m, 1H), 7.83−7.85 (m, 2H), 8.72 (br s, dis-
appeared on treatment with D2O, 1H) ppm. IR: ν 3259 cm
−1. Anal.
(C23H20ClNO3S (425.93)) C, H, Cl, N, S.
7-Fluoro-2-phenyl-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole
(40). Synthesized as 6, starting from 7-fluoro-2-phenyl-1H-indole (60).
Yield: 32%. Mp: 98−100 °C (from toluene). 1H NMR (DMSO-d6):
δ 3.54 (s, 6H), 3.57 (s, 3H), 6.30 (s, 2H), 7.05−7.10 (m, 2H), 7.31 (d,
J = 7.1 Hz, 1H), 7.46 (t, J = 7.2 Hz, 1H), 7.53 (t, J = 7.1 Hz, 2H), 7.88 (d,
J = 7.2 Hz, 2H), 12.46 (br s, disappeared on treatment with D2O, 1H)
ppm. IR: ν 3247 cm−1. Anal. (C23H20FNO3S (409.47)) C, H, F, N, S.
7-Methoxy-2-phenyl-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole
(42). Synthesized as 6, starting from 7-methoxy-2-phenyl-1H-indole
(61). Yield: 57%. Mp: 158−160 °C (from ethanol). 1H NMR (DMSO-
d6): δ 3.53 (s, 6H), 3.57 (s, 3H), 3.97 (s, 3H), 6.29 (s, 2H), 6.79−
6.81 (m, 1H), 7.04−7.08 (m, 2H), 7.40−7.49 (m, 3H), 7.83−7.86
(m, 2H), 12.09 (br s, disappeared on treatment with D2O, 1H) ppm.
IR: ν 3300 cm−1. Anal. (C24H23NO4S (417.45)) C, H, N, S.
6,7-Dichloro-2-phenyl-3-((3,4,5-trimethoxyphenyl)thio)-1H-in-
dole (44). Synthesized as 6, starting from 6,7-dichloro-2-phenyl-1H-
indole (62). Yield: 57%. Mp: 158−160 °C (from ethanol). 1H NMR
(DMSO-d6): δ 3.55 (s, 6H), 3.57 (s, 3H), 6.29 (s, 2H), 7.32 (d, J =
8.5 Hz, 1H), 7.44−7.55 (m, 4H), 7.83−7.85 (m, 2H), 12.44 (br s,
disappeared on treatment with D2O, 1H) ppm. IR: ν 1610, 3268 cm
−1.
Anal. (C23H19Cl2NO3S (460.37)) C, H, Cl, N, S.
General Procedure for the Preparation of 7, 9, 12, 14, 16, 19, 22,
24, 27, 29, 32, 34, 36, 38, 41, 43, and 45. Example: (4-Bromo-2-
phenyl-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)methanone (7). A
mixture of 46 (0.27 g, 1 mmol), 3,4,5-trimethoxybenzoyl chloride
(0.23 g, 1 mmol), and anhydrous aluminum chloride (0.13 g, 1 mmol) in
anhydrous 1,2-dichloroethane (2 mL) was placed into the microwave
cavity (closed vessel mode, Pmax = 250 psi). A starting microwave
irradiation of 150Wwas used, the temperature being ramped from 25 to
110 °C, with stirring. Once 110 °C was reached, taking about 1 min, the
reaction mixture was held at this temperature for 2 min. The reaction
mixture was quenched on 1 M HCl/crushed ice and extracted with
chloroform. The organic layer was washed with brine, dried, and filtered.
Removal of the solvent gave a residue that was purified by flash
chromatography (silica gel, ethyl acetate/n-hexane as eluent) to furnish
7 (0.09 g, 20%). Mp: 228−230 °C (from ethanol). 1H NMR (CDCl3):
δ 3.74 (s, 6H), 3.88 (s, 3H), 7.13−7.16 (m, 3H), 7.31−7.37 (m, 4H),
7.42−7.46 (m, 3H), 8.58 (br s, disappeared on treatment with D2O, 1H)
ppm. IR: ν 1618, 3344 cm−1. Anal. (C24H20BrNO4 (466.32)) C, H, Br, N.
(4-Chloro-2-phenyl-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)-
methanone (9). Synthesized as 7, starting from 47. Yield: 35%. Mp:
232−235 °C (from ethanol). 1H NMR (CDCl3): δ 3.72 (s, 6H), 3.94
Journal of Medicinal Chemistry Article
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(s, 3H), 7.17 (s, 2H), 7.19−7.23 (m, 2H), 7.30−7.33 (m, 3H), 7.38 (dd,
J = 2.0 and 7.0 Hz, 1H), 7.45−7.48 (m, 2H), 8.73 (br s, disappeared on
treatment with D2O, 1H) ppm. IR: ν 1618, 3169 cm
−1. Anal.
(C24H20ClNO4 (421.87)) C, H, Cl, N.
(4-Fluoro-2-phenyl-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)-
methanone (12). Synthesized as 7, starting from 48. Yield: 25%. Mp:
212−215 °C (from toluene). 1HNMR (DMSO-d6): δ 3.62 (s, 6H), 3.64
(s, 3H), 6.84−6.89 (m, 1H), 6.99 (s, 2H), 7.18−7.22 (m, 1H), 7.30−
7.35 (m, 4H), 7.42−7.44 (m, 2H), 12.34 (br s, disappeared on treatment
with D2O, 1H) ppm. IR: ν 1618, 3205 cm
−1. Anal. (C24H20FNO4
(405.42)) C, H, F, N.
(4-Methoxy-2-phenyl-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)-
methanone (14). Synthesized as 7, starting from 49. Yield: 51%. Mp:
144−146 °C (from toluene). 1HNMR (DMSO-d6): δ 3.53 (s, 3H), 3.64
(s, 6H), 3.69 (s, 3H), 6.55−6.57 (m, 1H), 7.02 (s, 2H), 7.09−7.16 (m,
2H), 7.29−7.39 (m, 3H), 7.49−7.51 (m, 2H), 11.95 (br s, disappeared
on treatment with D2O, 1H) ppm. IR: ν 1622, 3220 cm
−1. Anal.
(C25H23NO5 (417.45)) C, H, N.
(5-Bromo-2-phenyl-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)-
methanone (16). Synthesized as 7, starting from 50. Yield: 55%. Mp:
200−203 °C (from ethanol). 1HNMR (DMSO-d6): δ 3.57 (s, 3H), 3.58
(s, 6H), 6.78 (s, 2H), 7.23−7.27 (m, 3H), 7.35−7.41 (m, 3H), 7.48 (d,
J = 8.3 Hz, 1H), 8.09 (s, 1H), 12.40 (br s, disappeared on treatment with
D2O, 1H) ppm. IR: ν 1610, 3305 cm
−1. Anal. (C24H20BrNO4 (466.32))
C, H, Br, N.
(5-Chloro-2-phenyl-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)-
methanone (19). Synthesized as 7, starting from 51. Yield: 54%. Mp:
222−225 °C (from ethanol). 1HNMR (CDCl3): δ 3.69 (s, 6H), 3.81 (s,
3H), 6.94 (s, 2H), 7.24−7.30 (m, 4H), 7.33−7.40 (m, 3H), 8.07−8.08
(m, 1H), 8.81 (br s, disappeared on treatment with D2O, 1H) ppm. IR: ν
1610, 3340 cm−1. Anal. (C24H20ClNO4 (421.87)) C, H, Cl, N.
(5-Fluoro-2-phenyl-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)-
methanone (22). Synthesized as 7, starting from 52. Yield: 66%. Mp:
198−200 °C (from toluene). 1HNMR (DMSO-d6): δ 3.58 (s, 3H), 3.59
(s, 6H), 6.78 (s, 2H), 7.10−7.15 (m, 1H), 7.24−7.27 (m, 3H), 7.34−
7.37 (m, 2H), 7.51 (q, J = 4.6 Hz, 1H), 7.66 (dd, J = 2.5 and 10.1, 1H),
12.30 (br s, disappeared on treatment with D2O, 1H) ppm. IR: ν 1620,
3225 cm−1. Anal. (C24H20FNO4 (405.42)) C, H, F, N.
(5-Methoxy-2-phenyl-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)-
methanone (24). Synthesized as 7 starting from 53. Yield: 78%. Mp:
202−205 °C (from ethanol). 1HNMR (DMSO-d6): δ 3.58 (s, 3H), 3.59
(s, 6H), 3.78 (s, 3H), 6.78 (s, 2H), 6.90 (dd, J = 2.6 and 8.8 Hz, 1H),
7.24−7.25 (m, 3H), 7.32−7.34 (m, 2H), 7.41 (d, J = 8.8 Hz, 1H), 7.48
(d, J = 2.4 Hz, 1H), 12.11 (br s, disappeared on treatment with D2O,
1H) ppm. IR: ν 1652, 3195 cm−1. Anal. (C25H23NO5 (417.45)) C, H, N.
(6-Bromo-2-phenyl-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)-
methanone (27). Synthesized as 7, starting from 54. Yield: 40% as an
oil. 1H NMR (CDCl3): δ 3.68 (s, 6H), 3.81 (s, 3H), 6.94 (s, 2H), 7.23−
7.27 (m, 3H), 7.33−7.36 (m, 3H), 7.59 (s, 1H), 7.87 (d, J = 8.6 Hz, 1H),
8.84 (br s, disappeared on treatment with D2O, 1H) ppm. IR: ν 1610,
3304 cm−1. Anal. (C24H20BrNO4 (466.32)) C, H, Br, N.
(6-Chloro-2-phenyl-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)-
methanone (29). Synthesized as 7, starting from 55. Yield: 67%. Mp:
188−190 °C (from ethanol). 1HNMR (CDCl3): δ 3.63 (s, 6H), 3.79 (s,
3H), 6.93 (s, 2H), 7.20−7.24 (m, 4H), 7.31−7.33 (m, 2H), 7.41−7.43
(m, 1H), 7.91 (d, J = 8.6 Hz, 1H), 8.84 (br s, disappeared on treatment
with D2O, 1H) ppm. IR: ν 3319, 1618 cm
−1. Anal. (C24H20ClNO4
(421.87)) C, H, Cl, N.
(6-Fluoro-2-phenyl-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)-
methanone (32). Synthesized as 7, starting from 56. Yield: 25% as an
oil. 1H NMR (CDCl3): δ 3.68 (s, 6H), 3.80 (s, 3H), 6.94 (s, 2H), 7.05
(t, J = 8.9 Hz, 1H), 7.14 (d, J = 9.0 Hz, 1H), 7.26−7.33 (m, 5H), 7.99−
8.02 (m, 1H), 8.58 (br s, disappeared on treatment with D2O, 1H) ppm.
IR: ν 1621, 3265 cm−1. Anal. (C24H20FNO4 (405.42)) C, H, F, N.
(6-Methoxy-2-phenyl-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)-
methanone (34). Synthesized as 7, starting from 57. Yield: 63%. Mp:
186−188 °C (from toluene). 1HNMR (DMSO-d6): δ 3.59 (s, 9H), 3.83
(s, 3H), 6.80 (s, 2H), 6.85 (dd, J = 2.3 and 8.8 Hz, 1H), 6.97 (d, J =
2.2Hz, 1H), 7.24−7.26 (m, 3H), 7.32−7.34 (m, 2H), 7.79 (d, J = 8.8Hz,
1H), 12.01 (br s, disappeared on treatment with D2O, 1H) ppm. IR: ν
1610, 3302 cm−1. Anal. (C25H23NO5 (417.45)) C, H, N.
(7-Bromo-2-phenyl-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)-
methanone (36). Synthesized as 7, starting from 58. Yield: 58%. Mp:
188−190 °C (from ethanol). 1H NMR (CDCl3): δ 3.71 (s, 6H), 3.82
(s, 3H), 6.97 (s, 2H), 7.18 (t, J = 7.8 Hz, 1H), 7.28−7.32 (m, 3H), 7.42−
7.44 (m, 2H), 7.48 (d, J = 7.6 Hz, 1H), 7.99 (d, J = 8.0 Hz, 1H), 8.67
(br s, disappeared on treatment with D2O, 1H) ppm. IR: ν 1618,
3258 cm−1. Anal. (C24H20BrNO4 (466.32)) C, H, Br, N.
(7-Chloro-2-phenyl-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)-
methanone (38). Synthesized as 7, starting from 59. Yield: 64%. Mp:
148−150 °C (from ethanol). 1HNMR (DMSO-d6): δ 3.59 (s, 3H), 3.61
(s, 6H), 6.80 (s, 2H), 7.20−7.29 (m, 4H), 7.34 (dd, J = 1.0 and 7.6 Hz,
1H), 7.38−7.41 (m, 2H), 7.88 (dd, J = 1.0 and 8.0 Hz, 1H), 12.41 (br s,
disappeared on treatment with D2O, 1H) ppm. IR: ν 1607, 3215 cm
−1.
Anal. (C24H20ClNO4 (421.87)) C, H, Cl, N.
(7-Fluoro-2-phenyl-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)-
methanone (41). Synthesized as 7, starting from 60. Yield: 65%. Mp:
172−175 °C (from toluene). 1HNMR (DMSO-d6): δ 3.59 (s, 3H), 3.61
(s, 6H), 6.81 (s, 2H), 7.07−7.18 (m, 2H), 7.26−7.27 (m, 3H), 7.38−
7.40 (m, 2H), 7.72 (d, J = 7.8 Hz, 1H), 12.60 (br s, disappeared on
treatment with D2O, 1H) ppm. IR: ν 1615, 3254 cm
−1. Anal.
(C24H20FNO4 (405.42)) C, H, F, N.
(7-Methoxy-2-phenyl-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)-
methanone (43). Synthesized as 7, starting from 61. Yield: 20%. Mp:
185−188 °C (from ethanol). 1HNMR (DMSO-d6): δ 3.59 (s, 3H), 3.60
(s, 6H), 3.98 (s, 3H), 6.79 (s, 2H), 6.83 (d, J = 7.4 Hz, 1H), 7.11 (t, J =
7.9 Hz, 1H), 7.20−7.23 (m, 3H), 7.35−7.38 (m, 2H), 7.47−7.49
(m,1H), 12.24 (br s, disappeared on treatment with D2O, 1H) ppm.
IR: ν 1606, 3270 cm−1. Anal. (C25H23NO5 (417.45)) C, H, N.
(6,7-Dichloro-2-phenyl-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)-
methanone (45). Synthesized as 7, starting from 62. Yield: 23%. Mp:
218−220 °C (from ethanol). 1HNMR (DMSO-d6): δ 3.59 (s, 3H), 3.61
(s, 6H), 6.81 (s, 2H), 7.25−7.32 (m, 3H), 7.39−7.42 (m, 3H), 7.86 (d,
J = 8.5 Hz, 1H), 12.58 (br s, disappeared on treatment with D2O, 1H)
ppm. IR: ν 1607, 3271 cm−1. Anal. (C24H19Cl2NO4S (456.32)) C, H,
Cl, N, S.
General Procedure for the Preparation of 10, 20, 25, 30, and 39.
Example: 4-Chloro-2-phenyl-3-(3,4,5-trimethoxybenzyl)-1H-indole
(10). A borane−tetrahydrofuran complex (1.0 mL, 1.0 M in tetra-
hydrofuran) was slowly added to a cold solution of 9 (0.1 g, 0.24 mmol)
in anhydrous acetonitrile (1.4 mL) containing anhydrous methanol
(0.02 mL) under an Ar stream. The reaction was stirred at 50 °C for 1 h.
After cooling, the mixture was carefully diluted with water and extracted
with ethyl acetate. The organic layer was washed with brine, dried,
and filtered. Removal of the solvent gave a residue that was purified
by flash chromatography (silica gel, ethyl acetate/n-hexane as eluent)
to furnish 10 (0.01 g, 10%). Mp: 178−180 °C (from ethanol). 1H NMR
(CDCl3): δ 3.74 (s, 6H), 3.84 (s, 3H), 4.45 (s, 2H), 6.44 (s, 2H),
7.10−7.15 (m, 2H), 7.33 (dd, J = 2.2 and 6.8 Hz, 1H), 7.41−7−47
(m, 3H), 7.51−7.53 (m, 2H), 8.29 (br s, disappeared on treatment
with D2O, 1H) ppm. IR: ν 3358 cm
−1. Anal. (C24H22ClNO3 (407.89))
C, H, Cl, N.
5-Chloro-2-phenyl-3-(3,4,5-trimethoxybenzyl)-1H-indole (20).
Synthesized as 10, starting from 19. Yield: 41%. Mp: 172−175 °C
(from ethanol). 1H NMR (CDCl3): δ 3.76 (s, 6H), 3.82 (s, 3H), 4.16 (s,
2H), 6.41 (s, 2H), 7.15 (dd, J = 2.0 and 8.6 Hz, 1H), 7.31 (d, J = 8.6 Hz,
1H), 7.37−7.39 (m, 1H), 7.42−7.46 (m, 3H), 7.51−7.54 (m, 2H), 8.23
(br s, disappeared on treatment with D2O, 1H) ppm. IR: ν 3340 cm
−1.
Anal. (C24H22ClNO3 (407.89)) C, H, Cl, N.
5-Methoxy-2-phenyl-3-(3,4,5-trimethoxybenzyl)-1H-indole (25).
Synthesized as 10, starting from 24. Yield: 26%. Mp: 137−139 °C
(from ethanol). 1HNMR (DMSO-d6): δ 3.59 (s, 3H), 3.60 (s, 6H), 3.72
(s, 3H), 4.14 (s, 2H), 6.48 (s, 2H), 6.76 (dd, J = 2.4 and 8.9Hz, 1H), 6.97
(d, J = 2.4 Hz, 1H), 7.27 (d, J = 8.9 Hz, 1H), 7.35−7.39 (m, 1H), 7.50 (t,
J = 7.4 Hz, 2H), 7.61−7.64 (m, 2H), 11.12 (br s, disappeared on
treatment with D2O, 1H) ppm. IR: ν 3361 cm
−1. Anal. (C25H25NO4
(403.47)) C, H, N.
6-Chloro-2-phenyl-3-(3,4,5-trimethoxybenzyl)-1H-indole (30).
Synthesized as 10, starting from 29. Yield: 41%. Mp: 187−185 °C
(from ethanol). 1H NMR (CDCl3): δ 3.73 (s, 6H), 3.84 (s, 3H), 4.21 (s,
2H), 6.44 (s, 2H), 7.07 (dd, J = 2.0 and 8.4 Hz, 1H), 7.38−7.42 (m, 3H),
Journal of Medicinal Chemistry Article
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7.45−7.49 (m, 2H), 7.53−7.56 (m, 2H), 8.25 (br s, disappeared on
treatment with D2O, 1H) ppm. IR: ν 3332 cm
−1. Anal. (C24H22ClNO3
(407.89)) C, H, Cl, N.
7-Chloro-2-phenyl-3-(3,4,5-trimethoxybenzyl)-1H-indole (39).
Synthesized as 10, starting from 38. Yield: 41%. Mp: 156−158 °C
(from ethanol). 1H NMR (CDCl3): δ 3.74 (s, 6H), 3.83 (s, 3H), 4.22 (s,
2H), 6.44 (s, 2H), 7.05 (t, J = 7.8 Hz, 1H), 7.22−7−24 (m, 1H), 7.39−
7.45 (m, 2H), 7.48−7.51 (m, 2H), 7.59−7.61 (m, 2H), 8.34 (br s,
disappeared on treatment with D2O, 1H) ppm. IR: ν 3347 cm
−1. Anal.
(C24H22ClNO3 (407.89)) C, H, Cl, N.
Preparation of 5-Bromo-2-phenyl-3-(3,4,5-trimethoxybenzyl)-1H-
indole (17). A mixture of 16 (0.25 g, 0.54 mmol), triethylsilane (0.14 g,
0.19mL, 1.2 mmol), and trifluoroacetic acid (0.63 g, 0.41mL, 5.5mmol)
in 1,2-dichloroethane (2.0 mL) was placed into the microwave cavity
(closed vessel mode, Pmax =250 psi). A starting microwave irradiation of
250Wwas used, the temperature being ramped from 25 to 250 °C, with
rapid stirring and cooling. Once 250 °Cwas reached, taking about 2min,
the reaction mixture was held at this temperature for 20 min. The
reaction mixture was diluted with a saturated aqueous solution of
NaHCO3 and extracted with ethyl acetate. The organic layer was washed
with brine, dried, and filtered. Removal of the solvent gave a residue that
was purified by flash chromatography (silica gel, ethyl acetate/n-hexane
as eluent) to furnish 17 (0.04 g, 15%) as a colorless oil. 1H NMR
(CDCl3): δ 3.73 (s, 6H), 3.83 (s, 3H), 4.17 (s, 2H), 6.42 (s, 2H), 7.28 (s,
2H), 7.37−7.47 (m, 3H), 7.53−7.55 (m, 2H), 7.62 (s, 1H), 8.25 (br s,
disappeared on treatment with D2O, 1H) ppm. IR: ν 3338 cm
−1. Anal.
(C24H22BrNO3 (452.34)) C, H, Br, N.
Synthesis of Compounds 46−62. General Procedure for the
Preparation of 46, 54, and 56. Example: 4-Bromo-2-phenyl-1H-
indole (46).Amixture of 66 (0.1 g, 0.4 mmol), tin(II) chloride dihydrate
(1.35 g, 6 mmol), and 1 N HCl (0.92 mL) in glacial acetic acid
(4.80 mL) was heated at reflux temperature for 12 h. After cooling, the
reaction mixture was diluted with a saturated aqueous solution of
potassium carbonate and extracted with ethyl acetate. The organic layer
was washed with brine, dried, and filtered. Removal of the solvent gave a
residue that was purified by column chromatography (silica gel,
chloroform as eluent) to furnish 46 (0.02 g, 19%). Mp: 98−100 °C, lit.41
100−102 °C.
6-Bromo-2-phenyl-1H-indole (54). Synthesized as 46, starting from
67. Yield: 46%. Mp: 188−190 °C (from ethanol), lit.42 187 °C.
6-Fluoro-2-phenyl-1H-indole (56). Synthesized as 46, starting from
68. Yield: 24%. Mp: 170−171 °C (from ethanol), lit.43 171−172 °C.
General Procedure for the Preparation of 47−49, 55, 57, and 61.
Example: 4-Chloro-2-phenyl-1H-indole (47). A solution of 69 (2.0 g,
8 mmol) in anhydrous tetrahydrofuran (120 mL) was cooled at−40 °C,
and then a solution of tert-butyllithium (9.4 mL, 16 mmol, 7.7 M in
pentane) was added dropwise under an Ar stream. The reaction mixture
was stirred at 0 °C for 1 h and at 25 °C for 12 h, diluted with water, and
extracted with ethyl acetate. The organic layer was washed with brine,
dried, and filtered. Removal of the solvent gave a residue that was
purified by column chromatography (silica gel, dichloromethane as
eluent) to furnish 47 (0.56 g, 31%). Mp: 73−76 °C (from ethanol), lit.41
73−75 °C.
4-Fluoro-2-phenyl-1H-indole (48). Synthesized as 47 starting from
70. Yield: 52%. Mp: 60−62 °C (from ethanol), lit.41 62−64 °C.
4-Methoxy-2-phenyl-1H-indole (49). Synthesized as 47, starting
from 71. Yield: 34%.Mp: 100−103 °C (from ethanol), lit.44 103−105 °C.
6-Chloro-2-phenyl-1H-indole (55). Synthesized as 47, starting from
72. Yield: 18%. Mp: 176−177 °C (from ethanol), lit.45 180−181 °C.
6-Methoxy-2-phenyl-1H-indole (57). Synthesized as 47, starting
from 73. Yield: 31%.Mp: 170−173 °C (from ethanol), lit.46 173−176 °C.
7-Methoxy-2-phenyl-1H-indole (61). Synthesized as 47, starting
from 74. Yield: 28%. Mp: 83−87 °C (from ethanol), lit.47 85−86 °C.
General Procedure for the Preparation of 50−52, 58, 60, and 62.
Example: 5-Bromo-2-phenyl-1H-indole (50). Compound 75 (0.80 g,
2.8 mmol) was added by portions to polyphosphoric acid (8.0 g)
preheated at 110 °C. The reaction mixture was stirred at the same
temperature for 1 h and then quenched on crushed ice. The solid
was filtered and crystallized from ethanol to give 75 (0.65 g, 82%). Mp:
190−192 °C, lit.48 193−196 °C.
5-Chloro-2-phenyl-1H-indole (51). Synthesized as 50, starting from
76. Yield: 37%. Mp: 198−200 °C (from ethanol), lit.49 203−204 °C.
5-Fluoro-2-phenyl-1H-indole (52). Synthesized as 50, starting from
77. Yield: 37%. Mp: 180−185 °C (from ethanol), lit.50 181−183 °C.
7-Bromo-2-phenyl-1H-indole (58). Synthesized as 50, starting from
78. Yield: 14%. Mp: 115−117 °C (from ethanol), lit.51 117−118 °C. 1H
NMR (DMSO-d6): δ 6.97 (t, J = 7.7, 1H), 7.02 (s, 1H), 7.31−7.38 (m,
2H), 7.47 (t, J = 7.5 Hz, 2H), 7.56 (d, J = 7.8 Hz, 1H), 7.98−8.00 (m,
2H), 11.36 (br s, disappeared on treatment with D2O, 1H) ppm. IR: ν
3436 cm−1.
7-Fluoro-2-phenyl-1H-indole (60). Synthesized as 50, starting from
79. Yield: 25%. Mp: 122−125 °C (from ethanol). 1H NMR (DMSO-
d6): δ 6.91−7.00 (m, 3H), 7.33−7.38 (m, 2H), 7.47 (t, J = 7.5 Hz, 2H),
7.95 (d, J = 7.4 Hz, 2H), 11.85 (br s, disappeared on treatment with
D2O, 1H) ppm. IR: ν 3436 cm
−1.
6,7-Dichloro-2-phenyl-1H-indole (62). Synthesized as 50, starting
from 80. Yield: 27%. Mp: 105−108 °C (from ethanol). 1H NMR
(DMSO-d6): δ 7.03 (s, 1H), 7.21 (t, J = 8.4 Hz, 1H), 7.37 (t, J = 7.4 Hz,
1H), 7.46−7.55 (m, 3H), 7.99 (d, J = 8.0 Hz, 2H), 11.71 (br s,
disappeared on treatment with D2O, 1H) ppm. IR: ν 3248 cm
−1.
5-Methoxy-2-phenyl-1H-indole (53) was synthesized according to a
literature52 procedure.
7-Chloro-2-phenyl-1H-indole (59) was synthesized according to a
literature53 procedure.
Synthesis of Compounds 63−80. General Procedure for the
Preparation of 63−65. Example: 2-(2-Bromo-6-nitrophenyl)-1-
phenylethanol (63). To a solution of benzaldehyde (0.12 g, 0.1 mL,
1.1 mmol) and 2-bromo-6-nitrotoluene (0.25 g, 1.2mmol) in anhydrous
DMSO (5 mL) was added a solution of sodium ethoxide in anhydrous
ethanol (0.32 mL, 0.43 M). The reaction mixture was stirred at 25 °C
for 12 h, carefully diluted with water, and extracted with ethyl acetate.
The organic layer was washed with brine, dried, and filtered. Removal
of the solvent gave a residue that was purified by column chromato-
graphy (silica gel, ethyl acetate:n-hexane = 1:3 as eluent) to furnish 63
(0.15 g, 40%) as an oil. 1H NMR (DMSO-d6): δ 3.21−3.24 (m, 2H),
4.64 (d, J = 7.4 Hz, 1H), 5.48 (br s, disappeared on treatment with
D2O, 1H), 7.25−7.33 (m, 5H), 7.42 (t, J = 8.0 Hz, 1H), 7.84 (d, J =
8.0 Hz, 1H), 7.97 (d, J = 8.2 Hz, 1H) ppm. IR: ν 2961, 3030, 3063, 3325,
3560 cm−1.
2-(4-Bromo-2-nitrophenyl)-1-phenylethanol (64). Synthesized as
63, starting from 4-bromo-1-methyl-2-nitrobenzene. Yield: 44% as an
oil. 1H NMR (DMSO-d6): δ 3.07−3.12 (m, 2H), 4.69−4.73 (m, 1H),
5.43 (d, J = 4.5 Hz, disappeared on treatment with D2O, 1H), 7.21−7.25
(m, 1H), 7.28−7.33 (m, 4H), 7.39 (d, J = 8.3 Hz, 1H), 7.80 (dd, J =
1.7 and 8.2 Hz, 1H), 8.08−8.10 (m, 1H) ppm. IR: ν 2934, 3030, 3065,
3418 cm−1.
2-(4-Fluoro-2-nitrophenyl)-1-phenylethanol (65). Synthesized as
63, starting from 4-fluoro-1-methyl-2-nitrobenzene. Yield: 44% as an oil.
1H NMR (DMSO-d6): δ 3.12−3.14 (m, 2H), 4.68−4.73 (m, 1H), 5.40
(d, J = 4.4 Hz, disappeared on treatment with D2O, 1H), 7.22−7.33
(m, 5H), 7.46−7.51 (m, 2H), 7.81 (dd, J = 2.3 and 9.0 Hz, 1H) ppm.
IR: ν 2932, 3032, 3087, 3404 cm−1.
General Procedure for the Preparation of 66−68. Example: 2-(2-
Bromo-6-nitrophenyl)-1-phenylethanone (66). A solution of 63
(0.1 g, 0.3 mmol) in anhydrous dichloromethane (1.0 mL) was added
to a suspension of pyridinium chlorochromate (0.10 g, 0.47 mmol) in
the same solvent (2.0 mL). The reaction mixture was stirred at 25 °C for
1.5 h and diluted with water. The layers were separated, and the organic
phase was washed with brine, dried, and filtered. Removal of the solvent
gave a residue that was purified by column chromatography (silica gel,
chloroform:petroleum ether = 1:1 as eluent) to furnish 66 (0.06 g, 40%).
Mp: 113−115 °C (from ethanol). 1HNMR (DMSO-d6): δ 4.89 (s, 2H),
7.52−7.62 (m, 3H), 7.70 (t, J = 7.8 Hz, 1H), 8.05−8.10 (m, 4H) ppm.
IR: ν 1680 cm−1.
2-(4-Bromo-2-nitrophenyl)-1-phenylethanone (67). Synthesized as
66, starting from 64. Yield: 40%. Mp: 114−116 °C (from ethanol).
1H NMR (DMSO-d6): δ 4.87 (s, 2H), 7.53−7.60 (m, 3H), 7.70 (t, J =
7.1 Hz, 1H), 7.96−7.98 (m, 1H), 8.05 (d, J = 7.4 Hz, 2H), 8.28−8.30
(m, 1H) ppm. IR: ν 1686 cm−1.
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2-(4-Fluoro-2-nitrophenyl)-1-phenylethanone (68). Synthesized
as 66, starting from 65. Yield: 16%. Mp: 95−98 °C (from ethanol).
1H NMR (DMSO-d6): δ 4.88 (s, 2H), 7.56−7.72 (m, 5H), 8.03−8.06
(m, 3H) ppm. IR: ν 1680 cm−1.
General Procedure for the Preparation of 69−74. Example: N-(3-
Chloro-2-methylphenyl)benzamide (69). A solution of benzoyl
chloride (7.93 g, 6.55 mL, 56 mmol) in anhydrous tetrahydrofuran
(20 mL) was added dropwise to a solution of 3-chloro-2-methylaniline
(6.68 g, 5.64 mL, 47 mmol) and triethylamine (5.70 g, 7.85 mL,
56 mmol) at 0 °C in the same solvent (134 mL). The reaction was
heated at reflux for 2 h. After cooling, the mixture was diluted with water
and extracted with ethyl acetate. The organic layer was washed with
brine, dried, and filtered. Removal of the solvent gave a residue that
was triturated with diethyl ether to furnish 69 (5.66 g, 49%). Mp: 168−
170 °C, lit.54 170 °C. 1H NMR (CDCl3): δ 2.40 (s, 3H), 7.21 (t, J =
8.0 Hz, 1H), 7.26−7.29 (m, 1H), 7.51−7.55 (m, 2H), 7.58−7.62
(m, 1H), 7.75−7.80 (m, 2H; one proton disappeared after treatment
with D2O), 7.90−7.92 (m, 2H) ppm. IR: ν 1647, 3244 cm−1.
N-(3-Fluoro-2-methylphenyl)benzamide (70). Synthesized as 69,
starting from 3-fluoro-2-methylaniline. Yield: 67%. Mp: 150−152 °C
(from ethanol), lit.55 157−158 °C. 1H NMR (CDCl3): δ 2.25 (s, 3H),
6.93 (t, J = 9.0Hz, 1H), 7.20−7.27 (m, 1H), 7.52 (t, J = 7.7Hz, 2H), 7.59
(t, J = 7.3 Hz, 1H), 7.71−7.75 (m, 2H; one proton disappeared after
treatment with D2O), 7.88−7.91 (m, 2H) ppm. IR: ν 1670, 3230 cm−1.
N-(3-Methoxy-2-methylphenyl)benzamide (71). Synthesized as 69,
starting from 3-methoxy-2-methylaniline. Yield: 82%. Mp: 173−175 °C
(from ethanol), lit.56 177 °C. 1HNMR (DMSO-d6): δ 2.06 (s, 3H), 3.82
(s, 3H), 6.89 (d, J = 8.2 Hz, 1H), 6.94 (d, J = 7.8 Hz, 1H), 7.19 (t, J =
8.1 Hz, 1H), 7.53 (t, J = 7.6 Hz, 2H), 7.59 (t, J = 7.4 Hz, 1H), 7.98 (d, J =
7.2 Hz, 2H), 9.89 (br s, disappeared on treatment with D2O, 1H) ppm.
IR: ν 1649, 3229 cm−1.
N-(5-Chloro-2-methylphenyl)benzamide (72). Synthesized as 69,
starting from 5-chloro-2-methylaniline. Yield: 58%. Mp: 125−127 °C
(from ethanol), lit.57 121−123 °C.
N-(5-Methoxy-2-methylphenyl)benzamide (73). Synthesized as 69,
starting from 5-methoxy-2-methylaniline. Yield: 88%. Mp: 113−115 °C
(from ethanol). 1HNMR (DMSO-d6): δ 2.17 (s, 3H), 3.74 (s, 3H), 6.77
(dd, J = 2.6 and 8.4 Hz, 1H), 6.98 (d, J = 2.6 Hz, 1H), 7.17 (d, J = 8.4 Hz,
1H), 7.53 (t, J = 7.6 HZ, 2H), 7.59 (t, J = 7.3 Hz, 1H), 7.98 (d, J = 7.1 Hz,
2H), 9.83 (br s, disappeared on treatment with D2O, 1H) ppm. IR: ν
1650, 3299 cm−1.
N-(2-Methoxy-6-methylphenyl)benzamide (74). Synthesized as 69,
starting from 2-methoxy-6-methylaniline. Yield: 82%. Mp: 127−130 °C
(from ethanol). 1H NMR (DMSO-d6): δ 2.50 (s, 3H), 3.74 (s, 3H),
6.87−6.93 (m, 2H), 7.20 (t, J = 8.0 Hz, 1H), 7.49−7.60 (m, 3H), 8.00
(d, J = 7.3 Hz, 2H), 9.57 (br s, disappeared on treatment with D2O, 1H)
ppm. IR: ν 1647, 3360 cm−1.
General Procedure for the Preparation of 75−80. Example: 1-(4-
Bromophenyl)-2-(1-phenylethylidene)hydrazine (75). A mixture of
(4-bromophenyl)hydrazine hydrochloride (3.35 g, 15 mmol), aceto-
phenone (1.20 g, 1.16 mL, 10 mmol), and sodium acetate (1.23 g,
15 mmol) in ethanol (15 mL) was placed into the microwave cavity
(open vessel mode). Microwave irradiation of 250 W was used, the
temperature being ramped from 25 to 80 °C. Once 80 °C was reached,
taking about 1 min, the reaction mixture was held at this temperature
for 5 min, with stirring and cooling. The reaction mixture was cooled to
0 °C, filtered, washed with petroleum ether, and dried to give 76 (0.90 g,
30%). Mp: 118−120 °C (from ethanol). 1H NMR (CDCl3): δ 2.25 (s,
3H), 7.08 (d, J = 8.9 Hz, 2H), 7.35−7.41 (m, 6H; one proton
disappeared after treatment with D2O), 7.83 (d, J = 8.5 Hz, 2H) ppm.
IR: ν 3353 cm−1.
1-(4-Chlorophenyl)-2-(1-phenylethylidene)hydrazine (76). Syn-
thesized as 75, starting from (4-chlorophenyl)hydrazine hydrochloride.
Yield: 25%. Mp: 105−107 °C (from ethanol), lit.58 100−102 °C.
1H NMR (CDCl3): δ 2.25 (s, 3H), 7.12 (d, J = 8.8 Hz, 2H), 7.24 (d, J =
8.8 Hz, 2H), 7.31−7.35 (m, 2H; one proton disappeared after treatment
with D2O), 7.40 (t, J = 7.0 Hz, 2H), 7.79 (d, J = 7.1 Hz, 2H) ppm.
IR: ν 3352 cm−1.
1-(4-Fluorophenyl)-2-(1-phenylethylidene)hydrazine (77). Synthe-
sized as 75, starting from (4-fluorophenyl)hydrazine hydrochloride.
Yield: 95%. Mp: 110−112 °C (from ethanol), lit.59 107 °C. 1H NMR
(DMSO-d6): δ 2.25 (s, 3H), 7.00−7.10 (m, 2H), 7.22−7.29 (m, 3H),
7.38 (t, J = 7.3 Hz, 2H), 7.78 (d, J = 7.2 Hz, 2H), 9.31 (br s, disappeared
on treatment with D2O, 1H) ppm. IR: ν 3380 cm
−1.
1-(2-Bromophenyl)-2-(1-phenylethylidene)hydrazine (78). Syn-
thesized as 75, starting from (2-bromophenyl)hydrazine hydrochloride.
Yield: 86%. Mp: >300 °C (from ethanol). Spectral data were consistent
with those reported in the literature.60
1-(2-Fluorophenyl)-2-(1-phenylethylidene)hydrazine (79). Synthe-
sized as 75, starting from (2-fluorophenyl)hydrazine hydrochloride.
Yield: 68%. Mp: >300 °C (from ethanol). 1H NMR (DMSO-d6): δ 2.32
(s, 3H), 6.79−6.84 (m, 1H), 7.13−7.17 (m, 2H), 7.34−7.43 (m, 3H),
7.56−7.59 (m, 1H), 7.80−7.83 (m, 2H), 8.64 (br s, disappeared on
treatment with D2O, 1H) ppm. IR: ν 3380 cm
−1.
1-(2,3-Dichlorophenyl)-2-(1-phenylethylidene)hydrazine (80).
Synthesized as 75, starting from (2,3-dichlorophenyl)hydrazine hydro-
chloride. Yield: 79%.Mp: 112−115 °C. 1HNMR (DMSO-d6): δ 2.36 (s,
3H), 7.09 (dd, J = 1.4 and 7.9 Hz, 1H), 7.31 (t, J = 8.4, 1H), 7.37−7.45
(m, 3H), 7.60 (dd, J = 1.3 and 8.4 Hz, 1H), 7.84−7.87 (m, 2H), 8.40
(br s, disappeared on treatment with D2O, 1H) ppm. IR: ν 3270 cm
−1.
Molecular Modeling. All molecular modeling studies were
performed on a MacPro dual 2.66 GHz Xeon running Ubuntu 14.
The tubulin structure was downloaded from the Protein Data Bank
(http://www.rcsb.org/, PDB codes 1SA06 and 4O2A29).6 Ligand
structures were built with MOE61 and minimized using the MMFF94x
force field until an RMSD gradient of 0.05 kcal mol−1 Å−1 was reached.
The docking simulations were performed using PLANTS18 on the 1SA0
crystal structure.
Biology. Tubulin Assembly. The reaction mixtures contained 0.8 M
monosodium glutamate (pH 6.6 with HCl in a 2 M stock solution),
10 μM tubulin, 4% (v/v) DMSO, and varying concentrations of drug.
Following a 15 min preincubation at 30 °C, samples were chilled on ice,
GTP to 0.4 mM was added, and turbidity development was followed
at 350 nm in a temperature-controlled recording spectrophotometer for
20 min at 30 °C. The extent of reaction was measured. Full experimental
details were previously reported.62
[3H]Colchicine Binding Assay. The reaction mixtures contained
1.0 μM tubulin, 5.0 μM [3H]colchicine, and 5.0 μM inhibitor and were
incubated for 10 min at 37 °C. Complete details were described
previously.63
Cell Cultures. Cell lines were obtained from the American Type
Culture Collection (ATCC), unless otherwise specified. MCF-7 breast
carcinoma, OVCAR-8, and NCI/ADR-RES cells were obtained from
the National Cancer Institute drug screening laboratory, and NB4 cells
andMV4−11 cells from the Deutsche Sammlung vonMikroorganismen
and Zellkulturen. All cell lines, except as indicated, were grown in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with
10% fetal bovine serum (FBS), 20 mM HEPES, 100 U/mL penicillin,
100 mg/mL streptomycin, and 1% L-glutamine; specific requirements
include the addition of sodium pyruvate (1−2% for RD rhabdomyo-
sarcoma, HepG2 hepatoma, and the three MDA breast carcinoma cell
lines) and glucose (1 g/L for RD and HepG2, 4.5 g/L for PC3 prostate
carcinoma). Cell lines were cultured at 37 °C in 5% CO2/95% air in a
humidified incubator. Treatments were initiated 24 h after cell seeding
using ATI compound diluted in 0.1% DMSO, the indicated reference
compound, or 0.1% DMSO vehicle, for 24−72 h as indicated.
Cell Viability Assays. For MCF-7 breast carcinoma and OVCAR-8
and NCI/ADR-RES ovary carcinoma cells, the methodology for
evaluation of growth was previously described, except that cells were
grown for 96 h for IC50 determinations.
64
MV4−11, NB4, A-549, NCI-H1975, Messa, and Messa/Dx5 cells
were seeded into 96-well plates (Corning Inc., Costar) at a density of
2 × 103 cells/well in 50 μL of the appropriate medium. For the MDA-
MB-468, MDA-MB-436, and MDA-MB-231 breast carcinoma cell lines,
the cells were plated in 100 μL ofmedium in 96-well plates at a density of
3.5 × 103 cells/well for MDA-MB-468, 3 × 103 cells/well for MDA-MB-
436, and 2 × 103 cells/well for MDA-MB-436. After 24 h, the cells were
treated with the inhibitor (0.39−100 nM) and then evaluated in MTT
assays as described.65 Statistical analysis was performed by analysis of
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variance (ANOVA) with Neumann−Keul’s multiple comparison test or
teh Kolmogorov−Smirnov test where appropriate.
For the PC-3, HepG2, and RD cell lines, the cells were seeded in
24-well plates at a density of 95 × 103 cells/100 μL well (PC-3 and RD)
or 120 × 103 cells/100 μL well (HepG2). After 24 h, the test compound
was added (0.01−25 μM) for 48 h. After removal of the medium, MTT
was added (500 μM final concentration in 500 μL/well of phosphate-
buffered saline (PBS)) and incubation continued at 37 °C for 2 h in the
dark. The formazan crystals were dissolved in 2-propanol containing
0.04 N HCl (200 μL). A550 in the wells was determined using a
Multiskan Spectrum Thermo Electron Corp. reader. IC50 values were
calculated by nonlinear regression analysis (GraphPad Prism statistics
software). Experiments were performed in triplicate. For HeLa cells,
7 × 103 cell aliquots were seeded in a flat-bottom 96-well tissue culture
plate and, after 24 h, were exposed to the inhibitor (10−100 nM) for
24 or 48 h. MTT (10 μL, 5 mg/mL) (Sigma-Aldrich) was added to each
well, and the cells were further incubated for 3 h at 37 °C. After
solubilization of the crystals with 2-propanol/0.04 N HCl, A570
measurements were made with an ELISA reader, and IC50 values were
derived from dose−response curves.
For the MV4−11, NB4 (AML), A-549, and NCI-H1975 (lung
adenocarcinoma) cell lines, cell growth was measured using CellTiter-
Flor (Promega), a nonlytic, single-reagent-addition fluorescence assay
that detects the relative number of living cells in samples after
experimental manipulation. The CellTiter-Fluor cell viability assay
measures the conserved and constitutive protease activity within live
cells and, therefore, acts as a marker for cell viability. NB4 and MV4−11
cells in exponential growth were incubated for 48 h with different
concentrations of the inhibitors. After 48 h, CellTiter-Fluor reagent was
added to the cell culture medium (1:1, v/v) and incubated for at least
90 min at 37 °C. A549 and NCI-H1975 cells were treated with the
inhibitor for 72 h, and then CellTiter-Fluor reagent was added to one-
fifth of the culture medium volume. Fluorescence was recorded
(excitation wavelength, 360 nm; emission wavelength, 535 nm), and
the IC50 was calculated using GraphPad software.
For the Messa and Messa/Dx5 (resistant) sarcoma cell lines, the
CellTiter-Glo luminescent cell viability assay was used (Promega,
Madison, WI). Cells in exponential growth were incubated for 72 h with
different concentrations of the inhibitor, and then the same volume of
CellTiter-Glo reagent was added. The solution was stirred for 2 min to
induce cell lysis. Luminescence was recorded after an additional 10 min.
IC50 values were calculated using nonlinear regression analysis
(GraphPad Prism statistics software).
For T98G andU343MG cells, growth wasmeasured by a colorimetric
MTS conversion assay, as previously reported.15
For D283medulloblastoma cells, 3× 105 D283 cells/well were plated
in a 24-multiwell dish. After 24 h, ATI derivative 44 or 81 (1 μM) was
added to the cells for the indicated time. Viability was evaluated with a
trypan blue assay.
Antibodies and Immunostaining. The following unconjugated
monoclonal antibodies (mAb’s) were used for immunostaining:
anti-MICA (MAB159227), anti-MICB (MAB236511), anti-ULBP1
(MAB170818), anti-ULBP2 (MAB165903), and anti-ULBP3
(MAB166510) from R&D Systems (Minneapolis, MN), anti-PVR
(SKII.4) kindly provided by Prof M. Colonna (Washington University,
St Louis, MO), anti-Nec-2 (R2.525) from BD Pharmingen (San Diego,
CA), and allophycocyanin (APC)-conjugated goat affinity purified
F(ab′)2 fragment to mouse IgG (GAM) from Jackson ImmunoResearch
Laboratories (West Grove, PA).
Flow Cytometry Analysis. A total of 3 × 105 HeLa cells were seeded
in tissue culture dishes. After ATI treatment, cell numbers were counted
using a Z1 Coulter particle counter (Beckman Coulter). Cell cycle phase
distribution was analyzed in permeabilized cells incubated with PI
(Sigma-Aldrich P4170, 0.04 mg/mL). SS and FL-3 parameters were
acquired on a linear amplification scale, and FS and Fl2 on a log scale.
Cell aggregates were gated out on the biparametric graph FL-3lin/ratio.
Apoptosis was determined as the proportion of cells exhibiting a DNA
content lower than 2 N after gating out cell debris on the biparametric
graph FS/SS using the WinMDI software. Cell death was analyzed in
200 000 cell aliquots in binding buffer (10 mMHEPES/NaOH, pH 7.4,
140 mM NaCl, 2.5 mM CaCl2) incubated with annexin V−FITC
(Immunological Sciences, IK-11120) alone or annexin V−FITC in
combination with PI in the absence of permeabilizing agents. Cell
samples were analyzed in a Coulter Epics XL cytofluorometer (Beckman
Coulter) equipped with EXPO 32 ADC software. At least 10 000 cells
per sample were acquired.
IF and Image Analysis. Cells were seeded on sterile polylysine-
coated coverslips placed in tissue culture plates. After treatment with
ATI or VBL, as indicated, the cells were fixed with 3.7% para-
formaldehyde in PBS for 10 min at room temperature and then
permeabilized in 0.1% Triton-X100 in PBS for 5 min. Blocking and
antibody reactions were carried out in PBS/0.05% Tween 20 containing
3% BSA at room temperature using mouse anti-α-tubulin (1:2000, B-5-
1-2, Sigma-Aldrich) followed by FITC-conjugated goat antimouse IgG
(Jackson ImmunoResearch Laboratories). Chromosomal DNA was
stained with 4,6-diamidino-2-phenylindole (DAPI; 0.1 μg/mL) and
mounted in Vectashield (Vector Laboratories). Images were analyzed
using a Nikon Eclipse 90i microscope equipped with a Qicam Fast 1394
CCD camera (Qimaging). To resolve MT remnants or unstructured
tubulin foci, some of the acquired images were deconvoluted and
analyzed using the extended depth of focus on Z-serial optical sections
using a Nis-Elements AR 4.2 (Nikon).
IF and Flow Cytometry Ligand Analysis. NKG2D and DNAM-1
ligand surface expression onHeLa cells was analyzed by IF staining using
anti-MICA, anti-MICB, anti-ULBP1/2/3, anti-PVR, or anti-Nec2
unconjugated mAb’s, followed by secondary GAM/APC. Samples
were analyzed using a FACSCanto II (BD Biosciences, San Jose, CA).
Flow cytometric analysis was performed using the FlowJo software,
version 8.8.7 (TreeStar, Ashland, OR).
Degranulation Assay. NK cell-mediated cytotoxicity was evaluated
using the degranulation lysosomal marker CD107a as previously
described.66 As a source of effector cells, we used human peripheral
blood mononuclear cells (PBMCs) isolated from healthy donors by
Lymphoprep (Nycomed, Oslo, Norway) gradient centrifugation and
then cocultured for 10 days with an irradiated (30 Gy) Epstein−Barr
virus (EBV)-transformed B-cell line. Cells were grown in RPMI 8866 at
37 °C in a humidified 5% CO2 atmosphere. On day 10, the cell
population was routinely more than 90% CD56+CD16+CD3−, as
assessed by IF and flow cytometric analysis. After a 48 h treatment with
33 or 44, HeLa cells were incubated with activated NK cells at
effector:target (E:T) ratios of 1:1 in a flat-bottom 96-well tissue culture
plate in complete medium (DMEM (Life Technologies, Gaithersburg,
MD) supplemented with 10% FCS). The plates were incubated at 37 °C
in a 5% CO2 atmosphere for 2 h. Thereafter, the cells were washed with
PBS and incubated with anti-CD107a/APC (or cIgG/APC) for 45 min
at 4 °C. The cells were also stained with anti-CD3/FITC and anti-
CD56/PE to gate the CD3−CD56+ NK cell population.
Real-Time PCR. MICA, MICB, ULBP1, ULBP2, ULBP3, and PVR
mRNA expression was analyzed by real-time PCR. Total RNA from
HeLa cells was extracted using Trizol (Invitrogen) after a maximum of
24 h of drug treatment. Total RNA (1 μg) was used for cDNA first-
strand synthesis using oligo-dT (Promega, Madison, WI) in a 25 μL
reaction volume. To analyze ligand mRNA expression, the cDNA was
amplified in triplicate with the following primers: Hs00792952_m1 for
MICA, Hs00792952_m1 for MICB, Hs00197846_m1 for PVR,
Hs00607609_m1 for ULBP2, Hs00225909_m1 for ULBP3, and
Hs99999903_m1 for β-actin, all conjugated with fluorochrome FAM
(Applied Biosystems). The level of ligand expression was measured
using the threshold cycle value (Ct). The ΔCt was obtained by
subtracting the Ct value of the gene of interest (MICA, MICB, or PVR)
from the housekeeping gene (β-actin) Ct value. We usedΔCt of the NT
sample as the calibrator. The fold change was calculated according to the
formula 2−ΔΔCt, where ΔΔCt was the difference between ΔCt of the
sample and that of the calibrator (according to the formula, the value of
the calibrator in each run is 1).
Hh-Dependent Luciferase Reporter Assay. The luciferase assay was
performed in Shh-Light II (Shh-LII) cells, stably incorporating a Gli-
responsive luciferase reporter and the pRL-TK Renilla (normalization
control), treated for 48 h with SAG (200 nM) and the studied com-
pounds. Luciferase and Renilla activity were assayed with a dual-luciferase
Journal of Medicinal Chemistry Article
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assay system according to the manufacturer’s instructions (Promega,
Madison, WI). The results are expressed as luciferase/Renilla ratios and
represent the mean ± SD of three experiments, each performed in
triplicate.
LC−MS/MS Analytical Method. Samples were analyzed under the
following conditions: UFLC (Shimadzu) AC20 coupled with an API
3200 triple-quadrupole (ABSciex); eluents, (phase A) 95% water, 5%
acetonitrile + 0.1% HCOOH, (phase B) 5% water, 95% acetonitrile +
0.1% HCOOH; flow rate, 0.3 mL/min; column, Gemini-Nx 5 μm C18
110A (50 × 2.00 mm) at 35 °C; injection volume, 5 μL. LC−MS/MS
analyses were carried out using an ESI(+) interface in multiple reaction
monitoring mode.
Metabolic Stability.Compounds 33 and 44were dissolved inDMSO
in duplicate at a final concentration of 1 μMand preincubated for 10min
at 37 °C in potassium phosphate buffer (pH 7.4), 3 mM MgCl2, with
human or mouse liver microsomes (Xenotech) at a final concentration
of 0.5 mg/mL. After the preincubation period, the reactions were started
by adding the cofactor mixture (NADP, Glc6P, G6P-DH). Samples
were taken at times 0, 10, 20, 30, and 60 min. Acetonitrile was added to
stop the reaction and centrifuged. Supernatants were analyzed and
quantified by LC−MS/MS. A control sample without cofactors
was always added to check the stability of the test compounds in the
reaction mixtures. The reference standards were 7-ethoxycoumarin
and propranolol. A fixed concentration of verapamil was added in
every sample as an internal standard for LC−MS/MS. The percentage
of the area of the test compound remaining at the various incuba-
tion times was calculated with respect to the area of the compound at
time 0 min.
The rate constant, k (min−1), derived for the exponential decay
equation (peak area/IS vs time) was used to calculate the rate of intrinsic
clearance (CL) of the compound using the following equation:
μ = ×kCL ( L/min /mg of protein) ( /microsomal concn) 103
Aqueous Solubility. The solubilities of compounds 33 and 44 were
measured using a high-throughput screening assay format. Samples
prepared at the target concentration of 200 μMwere placed in a 96-well
filter plate and incubated at room temperature for 90 min. The plate was
then filtered, and solutions were analyzed by LC−MS/MS. Final
concentrations were evaluated by comparing the area under the curve of
the MeOH stock solution with those of the test compound solutions.
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